


Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

Graphical Abstract



Authors

Iosifina P. Foskolou,
Christian Jorgensen,
Katarzyna B. Leszczynska, ...,
Carmen Domene, Emily Flashman,
Ester M. Hammond

Correspondence

ester.hammond@oncology.ox.ac.uk

In Brief

Foskolou et al. demonstrate that in hypoxic conditions the small subunit of the RNR enzyme is switched from RRM2 to RRM2B in order to facilitate nucleotide production and ongoing replication. They identify specific residues within RRM2B that are responsible for maintaining activity in hypoxia.

Highlights

- RRM2B is induced in response to hypoxia in both cell models and patient datasets
- RRM2B retains activity in hypoxic conditions and is the favored RNR subunit in hypoxia
- Loss of RRM2B has detrimental consequences for cell fate, specifically in hypoxia
- RRM2B depletion enhanced hypoxic-specific apoptosis and increased radiosensitivity



Ribonucleotide Reductase Requires Subunit Switching in Hypoxia to Maintain DNA Replication

Iosifina P. Foskolou,¹ Christian Jorgensen,² Katarzyna B. Leszczynska,¹ Monica M. Olcina,¹ Hanna Tarhonskaya,⁴ Bauke Haisma,¹ Vincenzo D'Angiolella,¹ William K. Myers,³ Carmen Domene,^{2,4} Emily Flashman,⁴ and Ester M. Hammond^{1,5,*}

¹Cancer Research UK and Medical Research Council Oxford Institute for Radiation Oncology, Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK

²Department of Chemistry, King's College London, Britannia House, 7 Trinity Street, London SE1 1DB, UK

³Inorganic Chemistry Laboratory, University of Oxford, South Parks Road, Oxford OX1 3QR, UK

⁴Department of Chemistry, Chemistry Research Laboratory, University of Oxford, Mansfield Road, Oxford OX1 3TA, UK

⁵Lead Contact

*Correspondence: ester.hammond@oncology.ox.ac.uk

<http://dx.doi.org/10.1016/j.molcel.2017.03.005>

SUMMARY

Cells exposed to hypoxia experience replication stress but do not accumulate DNA damage, suggesting sustained DNA replication. Ribonucleotide reductase (RNR) is the only enzyme capable of de novo synthesis of deoxyribonucleotide triphosphates (dNTPs). However, oxygen is an essential cofactor for mammalian RNR (RRM1/RRM2 and RRM1/RRM2B), leading us to question the source of dNTPs in hypoxia. Here, we show that the RRM1/RRM2B enzyme is capable of retaining activity in hypoxia and therefore is favored over RRM1/RRM2 in order to preserve ongoing replication and avoid the accumulation of DNA damage. We found two distinct mechanisms by which RRM2B maintains hypoxic activity and identified responsible residues in RRM2B. The importance of RRM2B in the response to tumor hypoxia is further illustrated by correlation of its expression with a hypoxic signature in patient samples and its roles in tumor growth and radioresistance. Our data provide mechanistic insight into RNR biology, highlighting RRM2B as a hypoxic-specific, anti-cancer therapeutic target.

INTRODUCTION

Replication stress is a well-characterized tumor characteristic and has recently been considered as a potential new hallmark of cancer (Macheret and Halazonetis, 2015). Replication stress leads to the activation of the DNA damage response (DDR), which is associated with the early stages of cancer development (Bartkova et al., 2005; Gorgoulis et al., 2005). Hypoxia (low oxygen levels) is one of the most physiologically relevant driving forces of replication stress and is characterized by an increased number of stalled replication forks and significantly reduced replication rates. Importantly, hypoxia-induced replication stress

occurs in the absence of DNA damage (Olcina et al., 2013). Regions of hypoxia are observed in preneoplastic lesions in the majority of tumors. Hypoxia-induced replication stress is one of the factors proposed to contribute to the selection pressure to lose key components of the DDR, including p53 (Gorgoulis et al., 2005; Hammond et al., 2007; Graeber et al., 1996). The degree of tumor hypoxia is an indicator of poor patient prognosis due to resistance to most current therapies and increased metastatic spread (Begg et al., 2011; Höckel and Vaupel, 2001).

The importance of ribonucleotide reductase (RNR) lies in its unique ability to catalyze the rate-limiting step of the reduction of ribonucleotides (NDPs) to the corresponding deoxyribonucleotides (dNDPs), the precursors of DNA (Kolberg et al., 2004; Stubbe, 1998). Mammalian RNRs consist of two homodimeric subunits, which associate to form the holoenzyme. The large RRM1 dimer contains the catalytic site, whereas the smaller dimer (RRM2 or RRM2B) contains an oxygen-requiring di-iron tyrosyl-radical site, which is essential for catalysis (Kolberg et al., 2004; Uhlin and Eklund, 1994; Stubbe et al., 2003). RNR is highly regulated, as nucleotide imbalances can be detrimental to cell fate (Aye et al., 2015). Elevated deoxyribonucleotide triphosphate (dNTP) pools have been correlated with increased mutagenesis, while insufficient dNTPs cause replication stress and promote genomic instability (Bester et al., 2011; Burrell et al., 2013; Halazonetis et al., 2008; D'Angiolella et al., 2012).

Oxygen is essential for mammalian RNRs to oxidize the di-iron center found in the smaller subunit (RRM2 or RRM2B) (Huang et al., 2014). This generates the tyrosyl radical, which via a long-range pathway, transfers an electron to the catalytic site of RRM1, enabling the reduction of NDPs to dNDPs (Lundin et al., 2015; Kolberg et al., 2004; Stubbe et al., 2003). The mechanism by which iron is incorporated into the small subunit, and how oxygen activates the di-iron center for radical initiation, is still poorly understood and under intense investigation (Huang et al., 2014; Zhang et al., 2014). The oxygen dependency of the small RNR subunit has led to the logical assumption that RNR is inactive in severely hypoxic conditions, something that has been verified for the RRM1/RRM2 (R1/R2) version of the RNR enzyme (Brischwein et al., 1997; Chimpoy et al., 2000; Thelander et al., 1983; Reichard, 1993; Probst et al., 1989; Nordlund




Figure 1. Replication Is Compromised, but Not Abrogated, in Oxygen Levels below 0.1%

(A) RPA32 foci in RKO cells exposed to $<0.1\% \text{O}_2$ and representative images of RPA-negative (normoxia) and positive ($<0.1\% \text{O}_2$, 3 hr) cells. Scale bar, 10 μm .
 (B) Replication rates by DNA fiber analysis in RKO cells exposed to $<0.1\% \text{O}_2$ and representative images of DNA fibers in normoxia and $<0.1\% \text{O}_2$ (5 hr). Scale bar, 10 μm .
 (C and D) dNTP levels of purines (C) and pyrimidines (D) in RKO cells exposed to $<0.1\% \text{O}_2$ or the radical-scavenger hydroxyurea (HU) (2 mM, 6 hr). Data represent percentage of the control (normoxia).
 (E) Immunoblots of RNR subunits in RKO cells exposed to $<0.1\% \text{O}_2$ for the times indicated.
 (F) Representative images of RRM2B immunostaining in normoxia and $<0.1\% \text{O}_2$ (18 hr) in RKO cells. Scale bar, 20 μm .

(legend continued on next page)

and Reichard, 2006). In contrast, we demonstrate that RNR is able to maintain dNDP formation by switching subunits in hypoxic conditions (<0.1% O₂). This switch is critical to preserve sufficient nucleotide levels for ongoing replication and avoid DNA damage accumulation and apoptosis in hypoxia. Interestingly, we found that the RRM1/RRM2B (R1/R2B) version of the RNR enzyme retains activity in hypoxia due to adaptation of RRM2B to these conditions through two distinct mechanisms. Specifically, we determined that most of the tyrosyl radical in RRM2B remained stable when exposed to <0.1% O₂, a property that was diminished after disruption of the helix B open conformation (K37/K151) and the subsequent loss of the crosstalk between the two monomers. Furthermore, computational simulations suggest that Y164 plays a role in the fine-tuning of the oxygen-entering frequency of RRM2B, meaning it is likely to be a better oxygen-sequestering agent than RRM2. Collectively, our results reveal a critical role for the RNR (R1/R2B) enzyme in hypoxic conditions in maintaining sufficient dNTPs for ongoing replication and therefore preventing DNA damage, genomic instability, and subsequent loss of viability.

RESULTS

The RRM2B Subunit of RNR Is Induced in Response to Hypoxia

Cells in hypoxic conditions (<0.1% O₂) do not accumulate DNA damage, although they are characterized by the presence of replication stress, which leads to the activation of the DDR (Figures S1A and S1B) (Olcina et al., 2013). As predicted, hypoxia-induced replication stress leads to the accumulation of single-stranded DNA (ssDNA), which can be detected through the visualization of replication protein A (RPA) foci in S-phase cells (Pires et al., 2010). However, the percentage of cells in hypoxia with RPA foci decreases after prolonged exposure to these conditions (>6 hr) (Figure 1A). Therefore, our hypothesis is that although uncoupling of the helicases and polymerases occurs in hypoxia, replication can proceed. Using DNA fiber analysis, we confirmed that DNA replication is significantly slower in hypoxia (25% of normal rate) but is not completely abrogated (Figure 1B). dNTP incorporation assays were carried out in RKO cells exposed to hypoxia and demonstrated that, although the dNTP pools were disrupted (with the purines [dGTP, dATP] being more affected than the pyrimidines [dCTP, dTTP]), there was nucleotide availability in hypoxic conditions (Figures 1C and 1D). The differences observed between purine and pyrimidine pools are not fully understood. It has been suggested that pyrimidine levels persist due to compensatory activities of the pyrimidine salvage pathways or as a result of the deoxyuridine present in culture medium, which cells could uptake and phosphorylate, therefore contributing to pyrimidine levels, particularly dTTP (Eriksson et al., 1987; Bianchi et al., 1986). Interestingly, the pyrimidine salvage pathway has been

reported to be more efficient than the purine pathway, suggesting an explanation for why purine levels are more sensitive to hydroxyurea (HU) and potentially hypoxia (Reichard, 1988). Our data demonstrate sufficient nucleotide availability in hypoxia to allow replication to proceed, albeit at a compromised rate; thus raising the possibility that RNR is able to retain some activity in hypoxia.

Expression analysis of the RNR complex showed that the RRM2B protein is significantly induced (2- to 3.5-fold, depending on cell line) in response to hypoxia in cell lines, including colorectal, osteosarcoma, glioblastoma, and esophageal cancer cells, whereas the RRM2 small subunit decreased over time and the RRM1 remained unchanged or showed a slight decrease (Figures 1E, 1F, and S1C–S1F). As RKO cells showed the highest level of RRM2B expression, we chose it as a model line for the majority of our experiments (Figure S1G). Similar results were obtained when mRNA levels were assayed. *RRM2B* increased 4.6-fold after 24 hr in hypoxic conditions, whereas *RRM2* and *RRM1* mRNA levels decreased 12.3- and 2.5-fold, respectively (Figures 1G and S1H). Importantly, in silico TGCA (The Cancer Genome Atlas) analysis of colorectal adenocarcinoma patient cohorts demonstrated that *RRM2B* expression correlates significantly with the expression of a verified hypoxia signature (Figure 1H), suggesting that the oxygen-dependent overexpression of RRM2B also occurs in vivo (Li et al., 2014). In contrast, *RRM1* and *RRM2* expression did not correlate with the same hypoxic signature (Figures S1I and S1J). Interestingly, overexpression and genetic alterations in *RRM2B* correlated with worse overall and disease-free survival in colorectal cancer patients (Figures S1K–S1N).

The transcription factor HIF-1 (hypoxia-inducible factor 1) is known to mediate significant gene expression changes in response to hypoxia and has roles in DNA replication, DNA repair, and respiration (Hubbi et al., 2013; Fukuda et al., 2007; Crosby et al., 2009). Therefore, we investigated if the induction of RRM2B in hypoxia was dependent on HIF-1 α by utilizing RKO^{HIF-1 α +/+} and RKO^{HIF-1 α -/-} cells exposed to hypoxia (Figures 2A, S2A, and S2B). Interestingly, both the mRNA and the protein levels of RRM2B were induced in hypoxia irrespective of HIF-1 α status, in contrast to the well-documented HIF-1 α target GLUT1. Next, using RKO^{HIF-1 α +/+} cells exposed to either 2% or <0.1% O₂, we investigated the oxygen dependency of the induction of RRM2B protein. RRM2B was induced in response to the lower level of hypoxia (<0.1% O₂), where a robust p53 induction was also observed but did not increase in response to 2% O₂ despite HIF-1 α stabilization (Figure 2B). This finding is in agreement with our previous studies demonstrating that the lower level of hypoxia (<0.1% O₂) induces replication stress and that this is the signal that initiates the DDR (including p53 stabilization) (Hammond et al., 2002; Olcina et al., 2013).

RRM2B was first characterized as a p53-regulated RNR subunit (p53R2) (Tanaka et al., 2000). Here, further analysis of

(G) mRNA levels of RNR subunits in RKO cells in <0.1% O₂ normalized to 18S.

(H) Expression of RRM2B (log₁₀ conversion) in a colorectal adenocarcinoma TCGA dataset is shown against the hypoxia-inducible signature (log₁₀ conversion). For all panels (except H), n = 3 (biological replicates); for (A)–(D) and (G), data show means \pm SEM and one-way ANOVA analysis was applied; (ns) indicates a non-significant change. See also Figure S1.




Figure 2. RRM2B Is Induced in Hypoxia

(A) mRNA levels of *RRM2B* and *GLUT1* in RKO^{HIF-1α+/+} and RKO^{HIF-1α-/-} cells in <0.1% O₂ assayed by qPCR and normalized to 18S.
(B) Immunoblots of RKO cells exposed to 2% and <0.1% O₂ for the times indicated. p53 and RRM2B protein induction are observed only in <0.1% O₂.
(C and D) Immunoblots (C) and *RRM2B* mRNA levels (D) of HCT116^{p53+/+} and HCT116^{p53-/-} exposed to <0.1% O₂ for the times indicated.
(E) qPCR for p53 ChIP in RKO cells treated with Adriamycin (2 μM, 6 hr) or exposed to either normoxia or <0.1% O₂ (6 hr).
(F) Immunoblots of RKO cells treated as in (E).
(G) Expression of RRM2B (log₁₀ conversion) in the colorectal adenocarcinoma TCGA datasets is shown against hypoxia dependent p53-inducible group of genes (log₁₀ conversion).
(H) Immunoblots of RNR subunits in H1299^{p53-/-} (non-small cell lung carcinoma) cells exposed to <0.1% O₂ for the times indicated.
For all panels (except G), n = 3 (biological replicates); data in (A) and (D) represent mean ± SEM; and (E) shows representative mean of technical triplicates ± RQmax/RQmin. HIF-1α status and p53 status was examined by two-way ANOVA analysis; two-tailed Student's t test was applied in (E); (ns) indicates a non-significant change. See also Figure S2.

the molecular pathways mediating RRM2B induction in hypoxia demonstrated that the hypoxic overexpression of RRM2B occurs in a p53-dependent manner (Figures 2C, 2D, and S2C–S2H). To rule out the possibility of an indirect mechanism of induction of RRM2B by p53, chromatin immunoprecipitation (ChIP) assays were carried out and demonstrated that p53 binds directly to the p53-response element at the *RRM2B* locus lead-

ing to transcriptional overexpression (Figures 2E, 2F, and S2I–S2K). Interestingly, although p53 expression was increased in response to the DNA damaging agent Adriamycin, this did not correlate with increased p53 binding to the p53-response element in *RRM2B* (Figures 2E and 2F). Most importantly, analysis of the TCGA colorectal adenocarcinoma patient cohorts showed that *RRM2B* expression significantly correlated with a




Figure 3. Effects of RRM2B Depletion in Hypoxia

(A) Immunoprecipitation of RRM1 followed by immunoblotting for RRM2B and RRM2 in normoxia and <math><0.1\% \text{O}_2</math> (18 hr).

(B) dNTP levels in RKO cells treated with non-specific (siCTL) or siRRM2B and exposed to <math><0.1\% \text{O}_2</math> (16 hr).

(C) FACS analysis of U2OS cells treated with siCTL or siRRM2B and exposed to normoxia or <math><0.1\% \text{O}_2</math> (3 hr). Cells were pulsed with bromodeoxyuridine (BrdU) (20 μM) 30 min before collection.

(D) RPA32 foci in RKO^{RRM2B+/+} and RKO^{RRM2B-/-} cells after exposure to <math><0.1\% \text{O}_2</math>.

(E) 53BP1 foci in RKO^{RRM2B+/+} and RKO^{RRM2B-/-} cells exposed to normoxia or <math><0.1\% \text{O}_2</math> (6 hr).

(legend continued on next page)

recently identified group of hypoxia-inducible p53-dependent genes (Leszczynska et al., 2015), suggesting that hypoxia- and p53-dependent expression of *RRM2B* occurs in human cancers (Figure 2G). Interestingly, in p53 null cell lines (H1299^{p53^{-/-}}, HCT116^{p53^{-/-}}) a mild (1.3- to 1.7-fold) increase in RRM2B protein levels was also observed in hypoxia (Figures 2C and 2H). These findings suggest that additional post-translational p53-independent mechanisms exist for RRM2B stabilization and therefore the importance of RRM2B in hypoxic conditions.

RRM2B Replaces RRM2 in Hypoxia

In order to investigate the biological significance of hypoxia-induced RRM2B, we first verified that it forms a complex with the RRM1 subunit to reconstitute the R1/R2B holoenzyme in <0.1% O₂. Immunoprecipitation assays demonstrated that increased levels (5.3-fold) of RRM2B protein were bound to the RRM1 subunit in hypoxia whereas the levels of RRM2 bound to RRM1 decreased by 1.8-fold (Figures 3A, S3A, and S3B). Next, we asked if the hypoxia-formed R1/R2B enzyme was functional. Small interfering RNA (siRNA)-mediated loss of RRM2B led to significantly lower intracellular dNTP levels in hypoxia (50%–55% less pyrimidines and 25%–30% less purines compared to the control [siCTL]) (Figures 3B and S3C). In contrast, the loss of RRM2B did not significantly affect the dNTP pools in normoxic conditions (Figure S3D). In addition, fluorescence-activated cell sorting (FACS) analysis demonstrated that S-phase U2OS cells lacking RRM2B incorporate 37.5% less BrdU than the control-treated cells in hypoxia (Figures 3C and S3E). These findings demonstrate that depletion of RRM2B in hypoxia leads to further disruption of the dNTP pools and indicate that ongoing replication is disrupted.

To further investigate the hypoxic role of RRM2B, we used CRISPR/Cas9 technology to construct a RRM2B knockout cell line (RKO^{RRM2B^{-/-}}) (Figures S3F–S3I). RRM2B-depleted RKO cells (both knockout and siRNA treated) showed a persistent formation of RPA foci during long (24 hr) exposures to hypoxia, suggesting an accumulation of ssDNA and failure to complete DNA replication (Figures 3D and S4A–S4C). Furthermore, cells with reduced levels of RRM2B formed 53BP1 foci indicating the presence of double-strand breaks (DSBs) specifically in hypoxia (Figures 3E, 3F, and S4D–S4F). No evidence of elevated DNA damage was observed in control cells or in cells lacking RRM2B in normoxia; this was attributed to the RRM2-dependent supply of dNTPs when oxygen is abundant. The increased DSBs observed in hypoxic cells with depleted RRM2B correlated with (1) a significant loss of viability measured by colony survival assay (77% fewer cells survived after 24 hr of hypoxia when

RRM2B was silenced in comparison to siCTL) (Figure 3G) and (2) the induction of apoptosis as determined both morphologically and by induction of PARP cleavage (Figures 3H and S4G). Notably, xenograft tumors of RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} cells showed delayed tumor growth and increased radiosensitivity when RRM2B was lacking (Figures 3I and S4H). Additionally, a significant increase in apoptosis specifically in the hypoxic regions of the RRM2B^{-/-} tumors was observed (Figures 3J–3L) as determined by the presence of cleaved caspase-3 (apoptosis) in the pimonidazole (PIMO)-positive (hypoxic) regions. Increased apoptosis in the hypoxic fraction of the tumors offers a likely explanation for the increased radiosensitivity observed (Figure 3I).

The data presented so far suggest that the basal levels of dNTPs provided by R1/R2B (as opposed to R1/R2) are sufficient for ongoing replication in hypoxic cells, preventing the collapse of replication forks that would ultimately lead to DSBs and loss of viability. These data indicate that RRM2B contributes to the increased resistance of the most aggressive fraction of tumors; therefore, we investigated the hypoxic adaptation of RRM2B by determining the enzymatic properties of both forms of RNR enzyme (R1/R2 and R1/R2B) in normoxia and hypoxia.

RRM2B Retains Enzymatic Activity in Hypoxia

RRM1, RRM2, and RRM2B recombinant proteins were over-expressed and purified from *E. coli* (Figures S5A and S5B), without additional iron or reductants, to prevent the variability associated with in vitro assembly of the active cluster of the tyrosyl radical (Cotruvo and Stubbe, 2011). We quantified the iron bound to RRM2 and RRM2B using inductively coupled plasma (ICP) mass spectrometry and found comparable iron incorporation between the two recombinant proteins (Figure S5C). The level of iron incorporation was ~10% of the level that has been reported in a fully loaded RRM2, which would in turn predict lower enzymatic activity (Aye et al., 2012b; Ochiai et al., 1990).

The abilities of the two forms of the RNR enzyme (R1/R2B and R1/R2) to reduce cytidine diphosphate (CDP) (substrate) to deoxycytidine diphosphate (dCDP) (product) were assayed in normoxic and hypoxic conditions (<0.1% O₂). As hypothesized, the R1/R2B was able to sustain activity in both <0.1% O₂ and normoxia with no statistically significant difference in the total amount of dCDP formed under either condition after 30 min (Figure 4A). In fact, the R1/R2B enzyme continued converting CDP to dCDP for over 2 hr in hypoxia (Figures 4B and S5D). In contrast, the R1/R2 enzyme did not sustain activity in hypoxia (Figure 4C) and stopped producing dCDPs after 15 min in <0.1% O₂ (Figures 4D and S5D). Importantly, we verified that the R1/R2 enzyme did

(F) Representative images of 53BP1 foci in RRM2B-negative RKO cells treated with siRRM2B and exposed to normoxia or <0.1% O₂ (6 hr). Scale bar, 20 μm.

(G) Colony survival assay in RKO cells treated with siCTL or siRRM2B and exposed to normoxia or <0.1% O₂ (24 hr).









(H) Apoptosis detected morphologically in RKO cells treated with siCTL or siRRM2B and exposed to normoxia or <0.1% O₂ (19 hr).

(I) RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} cells were grown as xenografts in mice (n = 4 mice per each group). Where indicated, irradiation (10 Gy) was given when tumors reached ~100 mm³.

(J) Representative images of co-localization of cleaved caspase-3 (apoptosis) with PIMO (hypoxic areas) in RKO^{RRM2B^{+/+}} or RKO^{RRM2B^{-/-}} xenografts. Scale bars, 50 μm.

(K and L) Tumors were removed on day 28 post-implantation (from Figure S5H), and the level of apoptosis was quantified in normoxic areas (PIMO negative) (K) and hypoxic areas (PIMO positive) (L). Images from three different tumors (n = 3) per group were counted.

For all panels, n = 3 (biological replicates) unless otherwise stated. Data show mean ± SEM and two-tailed Student's t test was applied, except in (D), where one-way ANOVA analysis was applied, and (I), where two-way ANOVA analysis was applied. (ns) indicates a non-significant change. See also Figures S3 and S4.



I

EPR Sample	Spins / β subunit ($\times 10^{-3}$)	Hypoxia / Normoxia (%)
RRM2B Normoxia	9.84 ± 0.34	66 ± 3.35
RRM2B $<0.1\% \text{ O}_2$	6.45 ± 0.15	
RRM2 Normoxia	30 ± 1.4	43 ± 4
RRM2 $<0.1\% \text{ O}_2$	12.85 ± 0.75	

(legend on next page)

Table 1. O₂ Residence Times around the Fe Metallocenter for RRM2B and RRM2 Proteins

System	Time (ns)	O ₂ , Fe Residence Time (ns)		O ₂ Entering Events	Entering Frequency (%)
		1	2		
RRM2B monomer 1	300	O ₂ , 79	25	25	68
		O ₂ , 80	19		
		O ₂ , 120	36		
		O ₂ , 125	25		
RRM2B monomer 2	300	O ₂ , 93	49	8	22
		O ₂ , 107	9		
		O ₂ , 126	38		
		O ₂ , 175	103		
RRM2 monomer 1	300	O ₂ , 19	3	5	14
		O ₂ , 22	11		
		O ₂ , 37	2		
		O ₂ , 142	5		
RRM2 monomer 2	300	O ₂ , 8	19	0	0
		O ₂ , 65	20		
		O ₂ , 88	14		
		O ₂ , 122	9		

not stop dCDP formation in hypoxia due to lack of available CDP (Figure S5E). Collectively, these data suggest that the compromised R1/R2 activity observed at <0.1% O₂ was a result of limited oxygen availability. It is important here to state that the oxygen does not affect the stability of the tyrosyl radical, and it is only required for tyrosyl radical formation (Stubbe, 2003). Once assembled, the tyrosyl radical can catalyze multiple turnovers until regeneration is necessary, with mammalian R1/R2 being stable for 15–25 min in vitro (Cotruvo and Stubbe, 2011). The key difference observed between R1/R2B and R1/R2 in hypoxia offers a mechanistic explanation for why the R1/R2B form of RNR is preferred in hypoxic conditions. It should be noted that, as previously described, the overall activity of the RRM2B-containing RNR enzyme is significantly lower than that of the RRM2-containing RNR (Shao et al., 2004) (Figures 4B and 4D). Therefore, although our data suggest that R1/R2B is the preferred RNR enzyme in hypoxia, the levels of available nucleotides are still reduced compared to normoxia, thus explaining the continued replication stress in these conditions (Figure 1A).

Adaption of RRM2B to Hypoxic Environments

Given the differences in normoxic and hypoxic activity between RRM2B and RRM2, we compared the potential oxygen accessibility for the proteins using a modeling approach. Using the only available published structures of RRM2B (PDB: 3HF1) and RRM2 (PDB: 3VPN) (Smith et al., 2009), we investigated the theoretical differences and/or similarities in the dynamics of oxygen diffusion between the two proteins using classical molecular dynamics (MD) simulations. The intention of this study was to understand how molecular oxygen accesses the core of the protein and to probe whether any differences could be related to the activities of RRM2/RRM2B in normoxia versus hypoxia. Our analysis revealed three principal oxygen cavity tunnels (T1–T3) in both proteins, which could be employed as access points (Figures 4E, 4F, and S5F). Analysis of T1–T3 suggested that RRM2B could act as a better oxygen-sequestering agent than RRM2. Specifically, we found that the predicted oxygen-entering frequencies are greater for RRM2B (68% at monomer 1 and 22% at monomer 2) than for RRM2 (14% at monomer 1 and 0% at monomer 2) (Table 1), which indicate differential oxygen-turnover susceptibilities between RRM2B and RRM2. In addition, free-energy calculations of oxygen entry through tunnels T1, T2, and T3 (Figure S5G) suggest that the origin of the selectivity between RRM2B and RRM2 for oxygen turnover resided primarily in tunnels T2 and T3, meaning that the energy barriers for oxygen to cross T2 and T3 are higher for RRM2 than for RRM2B.


We then performed electron paramagnetic resonance (EPR) spectroscopy to monitor the stability of the tyrosyl radical of the two proteins in hypoxic conditions (Figures 4G and 4H). Strikingly, we observed that 66% ± 3.35% of the tyrosyl radical in RRM2B remained stable for 1 hr at 37°C in <0.1% O₂, while in the same conditions, only 43% ± 4% remained stable in RRM2 (Figure 4I). Collectively, our results provide compelling evidence that RRM2B is able to retain activity in hypoxia while the activity of RRM2 is compromised and therefore highlight a specific role for RRM2B in the hypoxic stress response.

Hypoxic Activity of RRM2B Is Dependent on K37/K151 and Y164

Despite the fact that RRM2 and RRM2B share 83% sequence homology, there are distinct functional and structural differences (Shao et al., 2004; Smith et al., 2009; Zhou et al., 2010; Xue et al., 2006; Wang et al., 2009b). The switch of C202 in RRM2 to Y164

Figure 4. RRM2B Retains Activity in Hypoxia

(A) Product formation (percentage of the maximum, where maximum is the dCDP levels at 30 min in normoxia) for R1/R2B enzyme in normoxia and <0.1% O₂. (B) dCDP (μM) in <0.1% O₂ for R1/R2B for the times indicated. Activity of R1/R2B enzyme at 37°C at 5 min in <0.1% O₂ was 19.57 nmol/min/mg RRM2B protein. Gray columns indicate the amount of dCDP formed up to 15 min in <0.1% O₂, and red columns indicate the amount of dCDP formed after 15 min in <0.1% O₂. (C) Product formation (percentage of the maximum, where maximum is the dCDP levels at 30 min in normoxia) for R1/R2 enzyme in normoxia and <0.1% O₂. (D) dCDP (μM) in <0.1% O₂ for R1/R2 for the times indicated. Activity of R1/R2 enzyme at 37°C at 5 min in <0.1% O₂ was 97.74 nmol/min/mg RRM2 protein. Gray columns indicate the amount of dCDP formed up to 15 min in <0.1% O₂, and red columns indicate the amount of dCDP formed after 15 min in <0.1% O₂. (E and F) Characterization of the oxygen tunnels (T1–T3) of RRM2B (E) and RRM2 (F). (G and H) EPR spectra of the tyrosyl radical of RRM2B (G) and RRM2 (H) in normoxia and <0.1% O₂, respectively. (I) Quantification of (G) and (H). Data present electron spins per β subunit. For all panels, n = 3 (biological replicates); for (A) and (C), data represent mean ± SEM and two-way ANOVA was applied; for (B) and (D), data represent mean ± SEM and two-tailed Student's t test was applied; (ns) indicates non significant change. See also Figure S5.



(legend on next page)

Table 2. O₂ Residence Times around the Fe Metallocenter for RRM2B Mutants

System	Time (ns)	O ₂ , Fe Residence Time (ns)	O ₂ Entering Events	Entering Frequency (%)	
Y164C monomer 1	300	O ₂ , 57	30	8	14
		O ₂ , 79	6		
		O ₂ , 124	9		
		O ₂ , 139	60		
Y164C monomer 2	300	O ₂ , 1	9	17	29
		O ₂ , 105	14		
		O ₂ , 167	7		
		O ₂ , 191	16		
K37E/K151E monomer 1	300	O ₂ , 37	30	37	64
		O ₂ , 40	32		
		O ₂ , 47	47		
		O ₂ , 27	27		
K37E/K151E monomer 2	300	O ₂ , 9	9	6	16
		O ₂ , 188	4		
		O ₂ , 190	5		
		O ₂ , 198	3		

in RRM2B results in an open phenylalanine channel specifically in RRM2B (Smith et al., 2009), which is connected with oxygen T3 (Figures S5F and S5H). It has been proposed that F183 in RRM2B versus Y221 in RRM2 contributes to the differences in the enzymatic activity between the two proteins (Zhou et al., 2010). In addition, RRM2B has unique antioxidant capabilities, which are partially due to the Y241 and Y331 residues (H279 and Y369 in RRM2) (Xue et al., 2006). Finally, RRM2B through K37 and K151 (E76 and E190 in RRM2) exhibits greater crosstalk between its secondary structures, which stabilizes helix B in an open conformation (Smith et al., 2009). Based on these key differences between RRM2 and RRM2B (Figure S6A) and in order to determine the regions of RRM2B responsible for hypoxic adaptation, we constructed, overexpressed, and purified seven recombinant RRM2B mutants: Y164C, Y164F, F183Y, K37E/K151E, Y241H, Y331F, and Q127K (Figure S6B). The Q127K mutant was generated as a negative control, as it diminishes

enzymatic activity due to disruption of the stability of the radical cluster (Zhou et al., 2010).

The seven purified mutants showed the same secondary structure, determined by circular dichroism, as the wild-type RRM2B recombinant protein (Figure S6C). The levels of iron incorporation were also similar for the mutant with the exception of Q127K, as expected (Figure S6D). Reduction of CDP to dCDP was assayed in hypoxia for these mutants. Sustained reduction of CDP to dCDP was observed for 2 hr for most mutants, except Y164C and K37E/K151E, which both appeared to stop reducing substrate after ~30 min in hypoxia, reminiscent of R1/R2 (Figures S6E–S6K). For these two mutants, we then compared dCDP formation in normoxia and hypoxia and found that the ability to reduce CDP to dCDP in hypoxia was compromised in both the K37E/K151E and Y164C mutants (Figures 5A and 5B). These results indicate that these specific residues are critical to the role of RRM2B in hypoxia and that without them, RRM2B activity is not sustained, similar to RRM2.

To further probe the role of K37/K151 and Y164, we performed additional EPR analyses and MD simulations. Using EPR spectroscopy, we observed that while most of the RRM2B mutants behaved as the WT-RRM2B, which retains 60%–79% of its tyrosyl radical in hypoxia (Figure S7A), the K37E/K151E mutant retained only 28% of its tyrosyl radical in these conditions (Figures 5C and 5D). Since K37/K151 residues affect helix B of RRM2B monomer 2, the bending angle of the helices was estimated and showed that helix B in RRM2B is in an open conformation (20°–25° bending angle), whereas in RRM2, it is closed (8°–10°) (Figure S7B). Interestingly, MD simulations for the K37E/K151E variant showed a closure of helix B after 300 ns from 20° to 8° bending angle, therefore resembling the closed conformation of RRM2 (Figures S7B and S7C). Although these are theoretical studies that provide only indications of the protein conformation, the distortion of helix B in monomer 2 of the K37E/K151E mutant could suggest loss of the essential crosstalk between the two monomers, which may explain the loss of tyrosyl radical stability in hypoxia as demonstrated by our EPR analysis.

Additionally, MD simulations showed a 4.8-fold lower oxygen entering frequency for the Y164C mutant in comparison to WT-RRM2B, while we did not observe any changes in the oxygen entering frequency for the K37E/K151E mutant (Table 2).

Figure 5. Critical Roles of K37/K151 and Y164 in RRM2B

(A and B) Product formation (percentage of the maximum, where maximum is the dCDP levels at 30 min in normoxia) for K37E/K151E (A) and Y164C (B) in normoxia and <0.1% O₂.

(C) EPR spectra of the tyrosyl radical of Y164C, K37E/K151E, and Q127K (as a negative control) in normoxia and <0.1% O₂.

(D) Quantification of (C). Data present electron spins per β subunit.

(E) The RRM2B phenylalanine network around Y164 and phenylalanine conformation in Y164C mutation. Distance plot reveals the effect of Y164C in F95-F197 distance. Color code: WT (black), Y164C (red).

(F and G) dATP (F) and dTTP (G) levels in RKO^{RRM2B-/-} cells transfected with CTL, WT, Y164C, or K37E/K151E and exposed to <0.1% O₂ (16 hr).

(H) Immunoblot for PARP cleavage in RKO^{RRM2B-/-} cells treated as in (F) and (G) plus Q127K and exposed to <0.1% O₂ (19 hr).

(I) Apoptosis detected morphologically in RKO^{RRM2B-/-} cells treated as in (H).

(J) Schematic representation of our proposed model. Hypoxia leads to severely compromised activity of RRM2, leading to replication stress. RRM2B is then induced through the DDR pathway to maintain ongoing replication. However, insufficient dNTPs are generated by R1/R2B, and replication stress is unresolved. The importance of RRM2B activity is that while it does not resolve replication stress, it does maintain replication fork integrity and prevents the accumulation of DNA damage and loss of genome stability.

For (A), n = 3; for (B), n = 4 (biological replicates) and two-way ANOVA was applied; for (C), n = 2 (biological replicates); for (F)–(I), n = 3 (biological replicates); data represent means ± SEM and two-tailed Student's t test was applied. See also Figures S6 and S7.

This could be explained by disruption of the Y164-F197 and Y164-F198 contacts in monomer 1 of RRM2B, which could cause side-chain rearrangement of F95 in the Y164C mutant. This rearrangement may result in F95 moving closer to F197, leading to closure of the RRM2B specific phenylalanine channel (Figures 5E and S5H), therefore explaining the lower oxygen-entering frequency in Y164C mutant.

Finally, in order to demonstrate that our findings are relevant in cells experiencing hypoxia and that the hypoxic adaptation of RRM2B depends on the identified residues (Y164 and K37/K151), we performed rescue experiments by transfecting our RKO^{RRM2B^{-/-}} cells with the following constructs: pRRM2B^{WT}, pRRM2B^{Y164C}, pRRM2B^{K37E/K151E}, and pcDNA3.1 (CTL). As expected, when WT-RRM2B was reintroduced, a significant increase in the intracellular nucleotide levels was observed in hypoxia, whereas reintroduction of Y164C and K37E/K151E showed significantly lower dNTP levels compared to WT-RRM2B (Figures 5F, 5G, S7D, and S7E). Additionally, by monitoring apoptosis, we observed that WT-RRM2B rescued the null phenotype from apoptosis, whereas loss of the key residues (Y164 and K37/K151) abrogated this rescue (Figures 5H and 5I), therefore validating our in vitro experiments and theoretical studies. Overall, we demonstrate the critical importance of the hypoxic induction of RRM2B to mitigate replication stress and determine the molecular adaptations of RRM2B to hypoxia to support this function (Figure 5J).

DISCUSSION

We identified that in response to the physiological stress of hypoxia, RNR responds by isoform switching favoring RRM2B over RRM2. In hypoxia the activity of RRM2 is severely compromised due to the lack of available oxygen, leading to replication stress. RRM2B is able to retain its activity in hypoxia and is therefore induced to compensate and facilitate ongoing replication. This property of RRM1/RRM2B, although not sufficient to resolve replication stress, does preserve replication fork integrity and prevent the accumulation of DNA damage in hypoxia. We verified that depletion of RRM2B results in lower dNTP levels in hypoxic cells and that this has detrimental consequences for cell fate (failure to complete DNA replication, DNA damage, and loss of viability). Importantly, loss of RRM2B in a xenograft model showed delayed tumor growth, increased radiosensitivity, and increased apoptosis specifically in hypoxic areas, further highlighting the biological importance of the hypoxic induction of RRM2B.

Our data suggest that RRM2B is capable of retaining activity in hypoxia through two mechanisms: (1) increased oxygen-entering frequency and (2) enhanced stability of the tyrosyl radical. Our MD analyses suggested that Y164 could increase the oxygen-entering frequency through oxygen tunnel T3 in monomer 1 by keeping F95 an optimum distance from F197. We also found that through the K37/K151 residues, the RRM2B protein retains 66%–70% of its tyrosyl radical in hypoxia. Interestingly, monomer 2 of RRM2B showed a higher oxygen-entering frequency than RRM2 (22% and 0%, respectively), suggesting that the two monomers of the small RNR subunits could react differently in the overall production of the tyrosyl

radical. It is possible that monomer 2 contributes more to the tyrosyl radical in RRM2B than in RRM2, possibly due to its helix B open conformation, and that this could be more relevant in hypoxic conditions. In support of this hypothesis, EPR spectra of the double mutant, K37E/K151E, showed a marked reduction in the tyrosyl radical content in hypoxia, but not in normoxia. We propose that the tyrosyl radical of monomer 2 is better protected in RRM2B, therefore contributing to the prolonged activity of the enzyme in hypoxic environments. Our proposed model, where both monomers contribute to tyrosyl radical formation, is in agreement with the established finding that the tyrosyl radical is equally distributed between each small subunit, suggesting the possibility of generation of two tyrosyl radicals per dimer (Cotruvo and Stubbe, 2011). It is important to note that our MD simulations were carried out with the only currently available crystal structure of human RRM2B protein (PDB: 3HF1), which has limitations in its active site configuration and specifically in the iron center. However, we considered it unlikely that as a result of this, there would be large conformational changes in the global structure of the protein compared to its native state, at least to a degree that would influence our MD analysis. Indeed, this is supported by the results of our recombinant mutant analysis and, most importantly, our rescue experiments using our RRM2B knockout cell line. Collectively, this work highlights the importance of Y164, K37, and K151 for RRM2B activity in hypoxia. It is important to note that the recombinant proteins used in our biochemical assays were assembled without additional iron. The biochemistry of RNR, especially the reconstitution of the tyrosyl radical, is extremely complex and not fully understood. Additional studies that also consider the relevant factors for accurate assembly are required and will likely further illuminate the role of RRM2B in both normoxia and hypoxia.

To date, mammalian RRM2B has been primarily associated with DNA repair and mitochondrial DNA synthesis (Wang et al., 2009b; Pontarin et al., 2012). However, it is probable that RRM2B has been evolutionarily maintained in order to be used as the hypoxic-specific RNR small subunit, especially as variants of RRM2B protein have been found to be responsible for continued cell division in anoxia tolerant vertebrates (Sandvik et al., 2012). Here, we propose that one of the principal functions of RRM2B is to act as the hypoxic-specific RNR subunit in order to be able to react promptly when this physiologically relevant stress occurs. It is tempting to speculate that through antioxidant and catalase-like properties (Xue et al., 2006), RRM2B might even play a role in increasing immediate oxygen availability.

Interestingly, a number of previous reports have demonstrated that RRM2B is frequently affected by copy-number changes, typically showing gains, in a broad range of cancers (Chae et al., 2016; Jørgensen et al., 2013). This has led to the suggestion that RRM2B is a tumor promoter (Aye et al., 2015). Our study demonstrates that increased RRM2B expression in hypoxia maintains replication and prevents DNA damage, therefore providing a plausible explanation for why RRM2B is so often amplified in cancers.

Our data suggest that targeting R1/R2B enzyme specifically in hypoxic tumor cells might be an effective therapeutic strategy. RNR is a well-established therapeutic target, and a number of RNR inhibitors (such as gemcitabine, clofarabine, hydroxyurea,

and triapine) are being used clinically (Manegold et al., 2000; Aye and Stubbe, 2011; Aye et al., 2012a; Levin, 1992; Sterkers et al., 1998; Hehlmann et al., 1993; Nutting et al., 2009). Interestingly, delivery of siRNA against RRM2 by phosphorothionate oligodeoxynucleotides (GTI-2040) (Lee et al., 2003) is in clinical trials for various solid tumors (Juhász et al., 2006; Leigh et al., 2009; Oh and Park, 2009). It is tempting to speculate that if this approach was modified to target RRM2B and was employed alongside patient stratification to identify those with significant tumor hypoxia, it may be an effective way to target the most aggressive and treatment-resistant fraction of tumors.

STAR★METHODS

Detailed methods are provided in the online version of this paper and include the following:

- KEY RESOURCES TABLE
- CONTACT FOR REAGENT AND RESOURCE SHARING
- EXPERIMENTAL MODEL AND SUBJECT DETAILS
- METHOD DETAILS
 - Cell culture and treatments
 - Hypoxia treatment
 - Immunoblotting and Immunofluorescence
 - RT-qPCR
 - Flow cytometry (FACS)
 - DNA Fiber analysis and dNTP pool determination
 - Immunoprecipitation (IP) and Chromatin IP (ChIP)
 - Colony survival and apoptosis
 - xCELLigence proliferation assay
 - Xenografts and tissue IF staining
 - TCGA RNA-sequencing (RNA-seq) analysis and analysis of colorectal cancer datasets
 - Protein overexpression and purification
 - dCDP formation assays
 - Determination of CDP/dCDP
 - Circular dichroism spectrometry
 - Inductively coupled plasma mass spectrometry (ICP-MS)
 - Electron paramagnetic resonance (EPR)
 - Molecular Dynamics (MD) simulations
 - MD equilibration protocol
 - Code availability
 - MD simulation analysis
 - Free-energy simulations of tunnel entry
 - Analysis of fenestrations
 - Statistical analysis
- DATA AND SOFTWARE AVAILABILITY

SUPPLEMENTAL INFORMATION

Supplemental Information includes seven figures and two tables and can be found with this article online at <http://dx.doi.org/10.1016/j.molcel.2017.03.005>.

AUTHOR CONTRIBUTIONS

I.P.F. conceived, designed, performed, and interpreted the majority of the experiments and wrote the manuscript. C.J. performed and interpreted the

MD simulations. K.B.L. performed the xenografts, immunohistochemistry (IHC), some experiments, and TCGA analysis. M.M.O. advised on some experiments and carried out TCGA analysis. B.H. assisted in developing the CRISPR clone. V.D. advised on the dNTP assay. H.T. assisted with enzyme assays. W.K.M. performed and analyzed the EPR studies. C.D. supervised, designed, and interpreted the MD simulations. E.F. supervised, designed, and interpreted in vitro enzymatic assays. E.M.H. conceived the project; conceived, designed, and interpreted the majority of the experiments; and wrote the manuscript. All authors commented on the manuscript.

ACKNOWLEDGMENTS

We thank Michael Stratford, Adam Hardy, Lisa Folkes, Mick Woodcock, Graham Brown, Philip Holdship, Ludovico Buti, Haoran Li, JoAnne Stubbe, and Yun Yen. CRUK Oxford Cancer Centre, CRUK Hartree Centre resources and the National Service were used for the Computational Chemistry Software. This work was supported by a Cancer Research UK (CR-UK) (H3RWGJ00.H307.1) grant (to E.M.H.), CR-UK Oxford Centre Prize DPhil Studentship C38302/A12981 (to I.P.F.), and a King's College London GTA studentship (to C.J.).

Received: October 11, 2016

Revised: February 13, 2017

Accepted: March 7, 2017

Published: April 13, 2017

SUPPORTING CITATIONS

The following references appear in the Supplemental Information: Hammond et al. (2006); Sherman and Fyfe (1989); Wang et al. (2007).

REFERENCES

- Ando, N., Li, H., Brignole, E.J., Thompson, S., McLaughlin, M.I., Page, J.E., Asturias, F.J., Stubbe, J., and Drennan, C.L. (2016). Allosteric inhibition of human ribonucleotide reductase by dATP entails the stabilization of a hexamer. *Biochemistry* 55, 373–381.
- Aye, Y., and Stubbe, J. (2011). Clofarabine 5'-di and -triphosphates inhibit human ribonucleotide reductase by altering the quaternary structure of its large subunit. *Proc. Natl. Acad. Sci. USA* 108, 9815–9820.
- Aye, Y., Brignole, E.J., Long, M.J., Chittuluru, J., Drennan, C.L., Asturias, F.J., and Stubbe, J. (2012a). Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers. *Chem. Biol.* 19, 799–805.
- Aye, Y., Long, M.J., and Stubbe, J. (2012b). Mechanistic studies of semi-carbazone triapine targeting human ribonucleotide reductase in vitro and in mammalian cells: tyrosyl radical quenching not involving reactive oxygen species. *J. Biol. Chem.* 287, 35768–35778.
- Aye, Y., Li, M., Long, M.J., and Weiss, R.S. (2015). Ribonucleotide reductase and cancer: biological mechanisms and targeted therapies. *Oncogene* 34, 2011–2021.
- Bartkova, J., Horejsí, Z., Koed, K., Krämer, A., Tort, F., Zieger, K., Gulberg, P., Sehested, M., Nesland, J.M., Lukas, C., et al. (2005). DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. *Nature* 434, 864–870.
- Begg, A.C., Stewart, F.A., and Vens, C. (2011). Strategies to improve radiotherapy with targeted drugs. *Nat. Rev. Cancer* 11, 239–253.
- Bester, A.C., Roniger, M., Oren, Y.S., Im, M.M., Sami, D., Chaoat, M., Bensimon, A., Zamir, G., Shewach, D.S., and Kerem, B. (2011). Nucleotide deficiency promotes genomic instability in early stages of cancer development. *Cell* 145, 435–446.
- Bianchi, V., Pontis, E., and Reichard, P. (1986). Changes of deoxyribonucleoside triphosphate pools induced by hydroxyurea and their relation to DNA synthesis. *J. Biol. Chem.* 261, 16037–16042.

- Brischwein, K., Engelcke, M., Riedinger, H.J., and Probst, H. (1997). Role of ribonucleotide reductase and deoxynucleotide pools in the oxygen-dependent control of DNA replication in Ehrlich ascites cells. *Eur. J. Biochem.* **244**, 286–293.
- Brooks, B.R., Brooks, C.L., 3rd, Mackerell, A.D., Jr., Nilsson, L., Petrella, R.J., Roux, B., Won, Y., Archontis, G., Bartels, C., Boresch, S., et al. (2009). CHARMM: the biomolecular simulation program. *J. Comput. Chem.* **30**, 1545–1614.
- Buck, M., Bouguet-Bonnet, S., Pastor, R.W., and MacKerell, A.D., Jr. (2006). Importance of the CMAP correction to the CHARMM22 protein force field: dynamics of hen lysozyme. *Biophys. J.* **90**, L36–L38.
- Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P., Sedivy, J.M., Kinzler, K.W., and Vogelstein, B. (1998). Requirement for p53 and p21 to sustain G2 arrest after DNA damage. *Science* **282**, 1497–1501.
- Burrell, R.A., McClelland, S.E., Endesfelder, D., Groth, P., Weller, M.C., Shaikh, N., Domingo, E., Kanu, N., Dewhurst, S.M., Gronroos, E., et al. (2013). Replication stress links structural and numerical cancer chromosomal instability. *Nature* **494**, 492–496.
- Cavallo, L., Kleinjung, J., and Fraternali, F. (2003). POPS: a fast algorithm for solvent accessible surface areas at atomic and residue level. *Nucleic Acids Res.* **31**, 3364–3366.
- Cerami, E., Gao, J., Dogrusoz, U., Gross, B.E., Sumer, S.O., Aksoy, B.A., Jacobsen, A., Byrne, C.J., Heuer, M.L., Larsson, E., et al. (2012). The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. *Cancer Discov.* **2**, 401–404.
- Chae, Y.K., Anker, J.F., Carneiro, B.A., Chandra, S., Kaplan, J., Kalyan, A., Santa-Maria, C.A., Platanius, L.C., and Giles, F.J. (2016). Genomic landscape of DNA repair genes in cancer. *Oncotarget* **7**, 23312–23321.
- Chimply, K., Tassotto, M.L., and Mathews, C.K. (2000). Ribonucleotide reductase, a possible agent in deoxyribonucleotide pool asymmetries induced by hypoxia. *J. Biol. Chem.* **275**, 39267–39271.
- Chipot, C., and Pohorille, A. (2007). *Free Energy Calculations* (Springer).
- Cohen, J., Kim, K., Posewitz, M., Ghirardi, M.L., Schulten, K., Seibert, M., and King, P. (2005). Molecular dynamics and experimental investigation of H(2) and O(2) diffusion in [Fe]-hydrogenase. *Biochem. Soc. Trans.* **33**, 80–82.
- Cohen, J., Arkhipov, A., Braun, R., and Schulten, K. (2006). Imaging the migration pathways for O₂, CO, NO, and Xe inside myoglobin. *Biophys. J.* **91**, 1844–1857.
- Cotruvo, J.A., and Stubbe, J. (2011). Class I ribonucleotide reductases: metal-locofactor assembly and repair in vitro and in vivo. *Annu. Rev. Biochem.* **80**, 733–767.
- Crosby, M.E., Kulshreshtha, R., Ivan, M., and Glazer, P.M. (2009). MicroRNA regulation of DNA repair gene expression in hypoxic stress. *Cancer Res.* **69**, 1221–1229.
- D'Angiolella, V., Donato, V., Forrester, F.M., Jeong, Y.T., Pellacani, C., Kudo, Y., Saraf, A., Florens, L., Washburn, M.P., and Pagano, M. (2012). Cyclin F-mediated degradation of ribonucleotide reductase M2 controls genome integrity and DNA repair. *Cell* **149**, 1023–1034.
- Dahl, A.C.E., Chavent, M., and Sansom, M.S.P. (2012). Bendix: intuitive helix geometry analysis and abstraction. *Bioinformatics* **28**, 2193–2194.
- Dang, D.T., Chen, F., Gardner, L.B., Cummins, J.M., Rago, C., Bunz, F., Kantsevov, S.V., and Dang, L.H. (2006). Hypoxia-inducible factor-1 α promotes nonhypoxia-mediated proliferation in colon cancer cells and xenografts. *Cancer Res.* **66**, 1684–1936.
- Darden, T., York, D., and Pedersen, L. (1993). Particle mesh Ewald: an N-log(N) method for Ewald sums in large systems. *J. Chem. Phys.* **98**, 10089.
- Darve, E., and Pohorille, A. (2001). Calculating free energies using average force. *J. Chem. Phys.* **115**, 9169.
- Darve, E., Rodríguez-Gómez, D., and Pohorille, A. (2008). Adaptive biasing force method for scalar and vector free energy calculations. *J. Chem. Phys.* **128**, 144120.
- Den Otter, W.K. (2000). Thermodynamic integration of the free energy along a reaction coordinate in Cartesian coordinates. *J. Chem. Phys.* **112**, 7283.
- Den Otter, W.K., and Briels, W.J. (1998). The calculation of free-energy differences by constrained molecular-dynamics simulations. *J. Chem. Phys.* **109**, 4139.
- Eriksson, S., Skog, S., Tribukait, B., and Wallström, B. (1987). Deoxyribonucleoside triphosphate metabolism and the mammalian cell cycle. Effects of hydroxyurea on mutant and wild-type mouse S49 T-lymphoma cells. *Exp. Cell Res.* **168**, 79–88.
- Foskolou, I.P., Biasoli, D., Olcina, M.M., and Hammond, E.M. (2016). Measuring DNA Replication in Hypoxic Conditions. *Adv. Exp. Med. Biol.* **899**, 11–25.
- Fraternali, F., and Van Gunsteren, W.F. (1996). An efficient mean solvation force model for use in molecular dynamics simulations of proteins in aqueous solution. *J. Mol. Biol.* **256**, 939–948.
- Fukuda, R., Zhang, H., Kim, J.W., Shimoda, L., Dang, C.V., and Semenza, G.L. (2007). HIF-1 regulates cytochrome oxidase subunits to optimize efficiency of respiration in hypoxic cells. *Cell* **129**, 111–122.
- Gao, J., Aksoy, B.A., Dogrusoz, U., Dresdner, G., Gross, B., Sumer, S.O., Sun, Y., Jacobsen, A., Sinha, R., Larsson, E., et al. (2013). Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. *Sci. Signal.* **6**, p11.
- Gorgoulis, V.G., Vassiliou, L.V., Karakaidos, P., Zacharatos, P., Kotsinas, A., Liloglou, T., Venere, M., Dittullo, R.A., Jr., Kastrinakis, N.G., Levy, B., et al. (2005). Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. *Nature* **434**, 907–913.
- Graeber, T.G., Osmanian, C., Jacks, T., Housman, D.E., Koch, C.J., Lowe, S.W., and Giaccia, A.J. (1996). Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. *Nature* **379**, 88–91.
- Halazonetis, T.D., Gorgoulis, V.G., and Bartek, J. (2008). An oncogene-induced DNA damage model for cancer development. *Science* **319**, 1352–1355.
- Hammond, E.M., Denko, N.C., Dorie, M.J., Abraham, R.T., and Giaccia, A.J. (2002). Hypoxia links ATR and p53 through replication arrest. *Mol. Cell. Biol.* **22**, 1834–1843.
- Hammond, E.M., Mandell, D.J., Salim, A., Krieg, A.J., Johnson, T.M., Shirazi, H.A., Attardi, L.D., and Giaccia, A.J. (2006). Genome-wide analysis of p53 under hypoxic conditions. *Mol. Cell. Biol.* **26**, 3492–3504.
- Hammond, E.M., Kaufmann, M.R., and Giaccia, A.J. (2007). Oxygen sensing and the DNA-damage response. *Curr. Opin. Cell Biol.* **19**, 680–684.
- Hehlmann, R., Heimpel, H., Hasford, J., Kolb, H.J., Pralle, H., Hossfeld, D.K., Queisser, W., Löffler, H., Heinze, B., Georgii, A., et al.; The German CML Study Group (1993). Randomized comparison of busulfan and hydroxyurea in chronic myelogenous leukemia: prolongation of survival by hydroxyurea. *Blood* **82**, 398–407.
- Höckel, M., and Vaupel, P. (2001). Tumor hypoxia: definitions and current clinical, biologic, and molecular aspects. *J. Natl. Cancer Inst.* **93**, 266–276.
- Huang, M., Parker, M.J., and Stubbe, J. (2014). Choosing the right metal: case studies of class I ribonucleotide reductases. *J. Biol. Chem.* **289**, 28104–28111.
- Hubbi, M.E., Kshitiz, Gilkes, D.M., Rey, S., Wong, C.C., Luo, W., Kim, D.H., Dang, C.V., Levchenko, A., and Semenza, G.L. (2013). A nontranscriptional role for HIF-1 α as a direct inhibitor of DNA replication. *Sci. Signal.* **6**, ra10.
- Humphrey, W., Dalke, A., and Schulten, K. (1996). VMD: visual molecular dynamics. *J. Mol. Graph.* **14**, 33–38, 27–28.
- Jorgensen, W.L., Chandrasekhar, J., Madura, J.D., Impey, R.W., and Klein, M.L. (1983). Comparison of simple potential functions for simulating liquid water. *J. Chem. Phys.* **79**, 926.
- Jørgensen, C.L., Ejlertsen, B., Bjerre, K.D., Balslev, E., Nielsen, D.L., and Nielsen, K.V. (2013). Gene aberrations of RRM1 and RRM2B and outcome of advanced breast cancer after treatment with docetaxel with or without gemcitabine. *BMC Cancer* **13**, 541.

- Juhasz, A., Vassilakos, A., Chew, H.K., Gandara, D., and Yen, Y. (2006). Analysis of ribonucleotide reductase M2 mRNA levels in patient samples after GTI-2040 antisense drug treatment. *Oncol. Rep.* **15**, 1299–1304.
- Kolberg, M., Strand, K.R., Graff, P., and Andersson, K.K. (2004). Structure, function, and mechanism of ribonucleotide reductases. *Biochim. Biophys. Acta* **1699**, 1–34.
- Langevin, P. (1908). On the theory of Brownian motion. *C.R. Acad. Sci.* **146**, 530–533.
- Lee, Y., Vassilakos, A., Feng, N., Lam, V., Xie, H., Wang, M., Jin, H., Xiong, K., Liu, C., Wright, J., and Young, A. (2003). GTI-2040, an antisense agent targeting the small subunit component (R2) of human ribonucleotide reductase, shows potent antitumor activity against a variety of tumors. *Cancer Res.* **63**, 2802–2811.
- Leighl, N.B., Laurie, S.A., Chen, X.E., Ellis, P., Shepherd, F.A., Knox, J.J., Goss, G., Burkes, R.L., Pond, G.R., Dick, C., et al. (2009). A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium. *J. Thorac. Oncol.* **4**, 1163–1169.
- Leszczynska, K.B., Foskolou, I.P., Abraham, A.G., Anbalagan, S., Tellier, C., Haider, S., Span, P.N., O'Neill, E.E., Buffa, F.M., and Hammond, E.M. (2015). Hypoxia-induced p53 modulates both apoptosis and radiosensitivity via AKT. *J. Clin. Invest.* **125**, 2385–2398.
- Leszczynska, K.B., Göttgens, E.L., Biasoli, D., Olcina, M.M., Ient, J., Anbalagan, S., Bernhardt, S., Giaccia, A.J., and Hammond, E.M. (2016). Mechanisms and consequences of ATM1N repression in hypoxic conditions: roles for p53 and HIF-1. *Sci. Rep.* **6**, 21698.
- Levin, V.A. (1992). The place of hydroxyurea in the treatment of primary brain tumors. *Semin. Oncol.* **19** (3 Suppl 9), 34–39.
- Li, B., Qiu, B., Lee, D.S., Walton, Z.E., Ochocki, J.D., Mathew, L.K., Mancuso, A., Gade, T.P., Keith, B., Nissim, I., and Simon, M.C. (2014). Fructose-1,6-bisphosphatase opposes renal carcinoma progression. *Nature* **513**, 251–255.
- Lundin, D., Berggren, G., Logan, D.T., and Sjöberg, B.M. (2015). The origin and evolution of ribonucleotide reduction. *Life (Basel)* **5**, 604–636.
- Macheret, M., and Halazonetis, T.D. (2015). DNA replication stress as a hallmark of cancer. *Annu. Rev. Pathol.* **10**, 425–448.
- Manegold, C., Zatloukal, P., Krejcy, K., and Blatter, J. (2000). Gemcitabine in non-small cell lung cancer (NSCLC). *Invest. New Drugs* **18**, 29–42.
- Miyamoto, S., and Kollman, P.A. (1992). SETTLE: An analytical version of the SHAKE and RATTLE algorithm for rigid water models. *J. Comput. Chem.* **13**, 952–962.
- Mizuno, H., Kitada, K., Nakai, K., and Sarai, A. (2009). PrognoScan: a new database for meta-analysis of the prognostic value of genes. *BMC Med. Genomics* **2**, 18.
- Nordlund, P., and Reichard, P. (2006). Ribonucleotide reductases. *Annu. Rev. Biochem.* **75**, 681–706.
- Nosé, S. (1984a). A molecular dynamics method for simulations in the canonical ensemble. *Mol. Phys.* **52**, 255–268.
- Nosé, S. (1984b). A unified formulation of the constant temperature molecular dynamics methods. *J. Chem. Phys.* **81**, 511–519.
- Nutting, C.M., van Herpen, C.M., Miah, A.B., Bhide, S.A., Machiels, J.P., Buter, J., Kelly, C., de Raucourt, D., and Harrington, K.J. (2009). Phase II study of 3-AP Triapine in patients with recurrent or metastatic head and neck squamous cell carcinoma. *Ann. Oncol.* **20**, 1275–1279.
- Ochiai, E., Mann, G.J., Gräslund, A., and Thelander, L. (1990). Tyrosyl free radical formation in the small subunit of mouse ribonucleotide reductase. *J. Biol. Chem.* **265**, 15758–15761.
- Oh, Y.K., and Park, T.G. (2009). siRNA delivery systems for cancer treatment. *Adv. Drug Deliv. Rev.* **61**, 850–862.
- Olcina, M.M., Foskolou, I.P., Anbalagan, S., Senra, J.M., Pires, I.M., Jiang, Y., Ryan, A.J., and Hammond, E.M. (2013). Replication stress and chromatin context link ATM activation to a role in DNA replication. *Mol. Cell* **52**, 758–766.
- Phillips, J.C., Braun, R., Wang, W., Gumbart, J., Tajkhorshid, E., Villa, E., Chipot, C., Skeel, R.D., Kalé, L., and Schulten, K. (2005). Scalable molecular dynamics with NAMD. *J. Comput. Chem.* **26**, 1781–1802.
- Piao, C., Jin, M., Kim, H.B., Lee, S.M., Amatya, P.N., Hyun, J.W., Chang, I.Y., and You, H.J. (2009). Ribonucleotide reductase small subunit p53R2 suppresses MEK-ERK activity by binding to ERK kinase 2. *Oncogene* **28**, 2173–2184.
- Pires, I.M., Bencokova, Z., Milani, M., Folkes, L.K., Li, J.L., Stratford, M.R., Harris, A.L., and Hammond, E.M. (2010). Effects of acute versus chronic hypoxia on DNA damage responses and genomic instability. *Cancer Res.* **70**, 925–935.
- Pontarin, G., Ferraro, P., Bee, L., Reichard, P., and Bianchi, V. (2012). Mammalian ribonucleotide reductase subunit p53R2 is required for mitochondrial DNA replication and DNA repair in quiescent cells. *Proc. Natl. Acad. Sci. USA* **109**, 13302–13307.
- Probst, H., Schiffer, H., Gekeler, V., and Scheffler, K. (1989). Oxygen dependent regulation of mammalian ribonucleotide reductase in vivo and possible significance for replicon initiation. *Biochem. Biophys. Res. Commun.* **163**, 334–340.
- Ran, F.A., Hsu, P.D., Wright, J., Agarwala, V., Scott, D.A., and Zhang, F. (2013). Genome engineering using the CRISPR-Cas9 system. *Nat. Protoc.* **8**, 2281–2308.
- Reichard, P. (1988). Interactions between deoxyribonucleotide and DNA synthesis. *Annu. Rev. Biochem.* **57**, 349–374.
- Reichard, P. (1993). From RNA to DNA, why so many ribonucleotide reductases? *Science* **260**, 1773–1777.
- Sandvik, G.K., Tomter, A.B., Bergan, J., Zoppellaro, G., Barra, A.L., Røhr, A.K., Kolberg, M., Ellefsen, S., Andersson, K.K., and Nilsson, G.E. (2012). Studies of ribonucleotide reductase in crucian carp—an oxygen dependent enzyme in an anoxia tolerant vertebrate. *PLoS ONE* **7**, e42784.
- Shao, J., Zhou, B., Zhu, L., Qiu, W., Yuan, Y.C., Xi, B., and Yen, Y. (2004). In vitro characterization of enzymatic properties and inhibition of the p53R2 subunit of human ribonucleotide reductase. *Cancer Res.* **64**, 1–6.
- Sherman, P.A., and Fyfe, J.A. (1989). Enzymatic assay for deoxyribonucleoside triphosphates using synthetic oligonucleotides as template primers. *Anal. Biochem.* **180**, 222–226.
- Smith, P., Zhou, B., Ho, N., Yuan, Y.C., Su, L., Tsai, S.C., and Yen, Y. (2009). 2.6 Å X-ray crystal structure of human p53R2, a p53-inducible ribonucleotide reductase. *Biochemistry* **48**, 11134–11141.
- Smith, J.J., Deane, N.G., Wu, F., Merchant, N.B., Zhang, B., Jiang, A., Lu, P., Johnson, J.C., Schmidt, C., Bailey, C.E., et al. (2010). Experimentally derived metastasis gene expression profile predicts recurrence and death in patients with colon cancer. *Gastroenterology* **138**, 958–968.
- Sterkers, Y., Preudhomme, C., Lai, J.L., Demory, J.L., Caulier, M.T., Wattel, E., Bordessoule, D., Bauters, F., and Fenaux, P. (1998). Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. *Blood* **91**, 616–622.
- Stubbe, J. (1998). Ribonucleotide reductases in the twenty-first century. *Proc. Natl. Acad. Sci. USA* **95**, 2723–2724.
- Stubbe, J. (2003). Di-iron-tyrosyl radical ribonucleotide reductases. *Curr. Opin. Chem. Biol.* **7**, 183–188.
- Stubbe, J., Nocera, D.G., Yee, C.S., and Chang, M.C. (2003). Radical initiation in the class I ribonucleotide reductase: long-range proton-coupled electron transfer? *Chem. Rev.* **103**, 2167–2201.
- Tanaka, H., Arakawa, H., Yamaguchi, T., Shiraiishi, K., Fukuda, S., Matsui, K., Takei, Y., and Nakamura, Y. (2000). A ribonucleotide reductase gene involved in a p53-dependent cell-cycle checkpoint for DNA damage. *Nature* **404**, 42–49.
- Tanaka, T., Ohkubo, S., Tatsuno, I., and Prives, C. (2007). hCAS/CSE1L associates with chromatin and regulates expression of select p53 target genes. *Cell* **130**, 638–650.

- Thelander, L., Gräslund, A., and Thelander, M. (1983). Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. *Biochem. Biophys. Res. Commun.* *110*, 859–865.
- Tuckerman, M., Berne, B.J., and Martyna, G.J. (1992). Reversible multiple time scale molecular dynamics. *J. Chem. Phys.* *97*, 1990–2001.
- Uhlen, U., and Eklund, H. (1994). Structure of ribonucleotide reductase protein R1. *Nature* *370*, 533–539.
- Van Gunsteren, W.F. (1989). Methods for calculation of free energies and binding constants: successes and problems. In *Computer Simulation of Biomolecular Systems: Theoretical and Experimental Applications*, W.F. van Gunsteren and P.K. Weiner, eds. (Escom), pp. 27–59.
- Verlet, L. (1967). Computer “experiments” on classical fluids. I. Thermodynamical properties of Lennard-Jones molecules. *Phys. Rev.* *159*, 98–103.
- Wang, P.H., and Blumberger, J. (2012). Mechanistic insight into the blocking of CO diffusion in [NiFe]-hydrogenase mutants through multiscale simulation. *Proc. Natl. Acad. Sci. USA* *109*, 6399–6404.
- Wang, J., Lohman, G.J., and Stubbe, J. (2007). Enhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases. *Proc. Natl. Acad. Sci. USA* *104*, 14324–14329.
- Wang, J., Lohman, G.J., and Stubbe, J. (2009a). Mechanism of inactivation of human ribonucleotide reductase with p53R2 by gemcitabine 5'-diphosphate. *Biochemistry* *48*, 11612–11621.
- Wang, X., Zhenchuk, A., Wiman, K.G., and Albertioni, F. (2009b). Regulation of p53R2 and its role as potential target for cancer therapy. *Cancer Lett.* *276*, 1–7.
- Wang, P.-H., Best, R.B., and Blumberger, J. (2011). A microscopic model for gas diffusion dynamics in a [NiFe]-hydrogenase. *Phys. Chem. Chem. Phys.* *13*, 7708–7719.
- Wang, P.-H., Bruschi, M., De Gioia, L., and Blumberger, J. (2013). Uncovering a dynamically formed substrate access tunnel in carbon monoxide dehydrogenase/acetyl-CoA synthase. *J. Am. Chem. Soc.* *135*, 9493–9502.
- Xue, L., Zhou, B., Liu, X., Wang, T., Shih, J., Qi, C., Heung, Y., and Yen, Y. (2006). Structurally dependent redox property of ribonucleotide reductase subunit p53R2. *Cancer Res.* *66*, 1900–1905.
- Zhang, Y., Li, H., Zhang, C., An, X., Liu, L., Stubbe, J., and Huang, M. (2014). Conserved electron donor complex Dre2-Tah18 is required for ribonucleotide reductase metallofactor assembly and DNA synthesis. *Proc. Natl. Acad. Sci. USA* *111*, E1695–E1704.
- Zhou, B., Liu, X., Mo, X., Xue, L., Darwish, D., Qiu, W., Shih, J., Hwu, E.B., Luh, F., and Yen, Y. (2003). The human ribonucleotide reductase subunit hRRM2 complements p53R2 in response to UV-induced DNA repair in cells with mutant p53. *Cancer Res.* *63*, 6583–6594.
- Zhou, B., Su, L., Yuan, Y.C., Un, F., Wang, N., Patel, M., Xi, B., Hu, S., and Yen, Y. (2010). Structural basis on the dityrosyl-diiron radical cluster and the functional differences of human ribonucleotide reductase small subunits hp53R2 and hRRM2. *Mol. Cancer Ther.* *9*, 1669–1679.

STAR★METHODS

KEY RESOURCES TABLE

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Antibodies		
Goat polyclonal anti-RRM1 (T-16)	Santa Cruz	Cat# sc-11733
Goat polyclonal anti-RRM2 (N-18)	Santa Cruz	Cat# sc-10844
Goat polyclonal anti-p53R2 (N-16) (RRM2B)	Santa Cruz	Cat# sc-10840
Mouse monoclonal anti-Chk1 (G-4)	Santa Cruz	Cat# sc-8408
Mouse monoclonal anti-p53 (DO-1)	Santa Cruz	Cat# sc-126
Rabbit polyclonal anti-p53 (FL-393)	Santa Cruz	Cat# sc-6243
Mouse monoclonal anti- β -Actin Antibody (AC-15)	Santa Cruz	Cat# sc-69879
Mouse anti-Human HIF-1 α Clone 54	BD Transduction Laboratories	Cat# 610958
Mouse anti-BrdU Clone B44	BD Transduction Laboratories	Cat# 347580
Rat monoclonal anti BrdU Clone BU1/75 (ICR1)	Bio-Rad	Cat# OB0030CX
Mouse monoclonal anti-RRM2 Clone 1E1	Bio-Rad	Cat# MCA3434Z
Rabbit polyclonal anti-KAP-1	Bethyl / Universal Biologicals	Cat# A300-274
Rabbit polyclonal anti-Phospho KAP-1 (S824)	Bethyl / Universal Biologicals	Cat# A300-767
Rabbit polyclonal anti-Phospho KAP-1 (S473)	BioLegend	Cat# 644602 RRID:AB_2241094
Rabbit polyclonal anti-53BP1	Novus Biologicals	Cat# NB100-904
Rabbit polyclonal anti-Phospho-p53 (Ser15)	Cell Signaling	Cat# 9284
Rat monoclonal anti-RPA32/RPA2 (4E4)	Cell Signaling	Cat# 2208
Rabbit polyclonal anti-Phospho-Chk1 (Ser296)	Cell Signaling	Cat# 2349
Rabbit polyclonal anti-Phospho-Chk1 (Ser317)	Cell Signaling	Cat# 2344
Rabbit polyclonal anti-Phospho-Chk1 (Ser345)	Cell Signaling	Cat# 2341
Rabbit polyclonal anti-PARP	Cell Signaling	Cat# 9542
Rabbit polyclonal anti-Cleaved Caspase-3 (Asp175)	Cell Signaling	Cat# 9661
Anti-mouse IgG, HRP-linked	Cell Signaling	Cat# 7076
Anti-rabbit IgG, HRP-linked	Cell Signaling	Cat# 7074
Rabbit polyclonal anti-beta Tubulin antibody	Abcam	Cat# ab6046
Mouse monoclonal anti-pimnidazole Clone 4.3.11.3)	Chemicon International	Cat# HP1-100
Alexa Fluor 680 goat anti-mouse IgG (H+L)	Invitrogen	Cat# A21057
Alexa Fluor 680 goat anti-rabbit IgG (H+L)	Invitrogen	Cat# A21076
Alexa Fluor 680 donkey anti-goat IgG (H+L)	Invitrogen	Cat# A21084
IRDye 800CW donkey anti-rabbit IgG	Li-Cor	Cat# 926-32213
IRDye 800CW donkey anti-mouse IgG	Li-Cor	Cat# 926-32212
Alexa Fluor 488-conjugated goat anti-rabbit IgG	Invitrogen	Cat# A11070
Alexa Fluor 488-conjugated donkey anti-rabbit IgG	Invitrogen	Cat# A21206
Alexa Fluor 488-conjugated goat anti-mouse IgG	Invitrogen	Cat# A11017
Alexa Fluor 488-conjugated donkey anti-goat IgG	Invitrogen	Cat# A11055
Alexa Fluor 594-conjugated goat anti-rabbit IgG	Invitrogen	Cat# A11072
Alexa Fluor 594-conjugated goat anti-rat IgG	Invitrogen	Cat# A11007
Alexa Fluor 594-conjugated goat anti-mouse IgG	Invitrogen	Cat# A11020
Alexa Fluor 594-conjugated donkey anti-goat IgG	Invitrogen	Cat# A11058
Alexa Fluor 555-conjugated goat anti-rat IgG	Invitrogen	Cat# A21434
Alexa Fluor 488-conjugated goat anti-mouse F(ab') ₂ fragment	Invitrogen	Cat# A11017
Pierce Recombinant Protein A/G	Thermo Fisher Scientific	Cat# 21186

(Continued on next page)

Continued

REAGENT or RESOURCE	SOURCE	IDENTIFIER
Bacterial and Virus Strains		
BL21-Gold(DE3) Competent Cells	Agilent Technologies	Cat# 230132
One Shot TOP10 Chemically Competent <i>E. coli</i>	Thermo Fisher Scientific	Cat# C404010
Chemicals, Peptides, and Recombinant Proteins		
Hydroxyurea (HU)	Sigma	Cat# H8627
Doxorubicin hydrochloride (Adriamycin)	Sigma	Cat# D1515
5-Bromo-2'-deoxyuridine (BrdU)	Sigma	Cat# B5002
Propidium iodide (PI)	Sigma	Cat# S7109
Protease Inhibitor Cocktail	Roche	Cat# 04693159001
CldU (5-chloro-2'-deoxyuridine)	Sigma	Cat# C6891
IdU (5-iodo-2'-deoxyuridine)	Sigma	Cat# I7125
Cytidine 5'-diphosphocholine sodium salt dehydrate (CDP)	Sigma	Cat# C9755
Protein G Sepharose, Fast Flow	Sigma	Cat# P3296
Isopropyl β -D-1-thiogalactopyranoside (IPTG)	Sigma	Cat# I6758
Deoxyadenosine 5'-Triphosphate, [8-3H(N)] (dATP-H3)	Perkin Elmer	Cat# NET268250UC
Deoxythymidine 5'-Triphosphate ((dTTP) Tetrasodium Salt) (dTTP-H3)	Perkin Elmer	Cat# NET520A250UC
TRIzol Reagent	Thermo Fisher Scientific	Cat# 15596018
DharmaFECT 1	Dharmacon	Cat# T-2001
Lipofectamine Ltx	Thermo Fisher Scientific	Cat# 15338100
ProLong Gold	Thermo Fisher Scientific	Cat# P36931
Critical Commercial Assays		
Hypoxyprobe-1 Kit for the Detection of Tissue Hypoxia	Chemicon International	Cat# HP1-100
Real-Time and Dynamic Monitoring of Cell Proliferation and Viability for Adherent Cells	ACEA Biosciences Inc/ Cambridge Biosc	Cat# 00380601050
SYBR Green PCR Master Mix	Applied Biosystems	Cat# 4309155
Verso cDNA Synthesis Kit	Thermo Fisher Scientific	Cat# AB1453B
HisTrap HP columns	GE Healthcare	Cat# 17-5248-02
QIAprep Spin Miniprep Kit	QIAGEN	Cat# 27106
QuickChange II XL Site-Directed Mutagenesis Kit	Agilent Technologies	Cat# 200521
QIAquick PCR Purification Kit	QIAGEN	Cat# 28106
QIAquick Gel Extraction Kit	QIAGEN	Cat# 28704
Deposited Data		
Original imaging data	this study	http://dx.doi.org/10.17632/bp95v48kgm.1
Experimental Models: Cell Lines		
RKO	ATCC	CRL-2577
HCT116	ATCC	CCL-247
H1299	ATCC	CRL-5803
U2OS	ATCC	HTB-96
U87-MG	ATCC	HTB-14
OE21	ECACC	96062201
RKOHIF-1 α +/+ and RKOHIF-1 α -/-	Dang L.H. Laboratory	Dang et al., 2006
HCT116p53+/+ and HCT116p53-/-	Vogelstein B. Laboratory	Bunz et al., 1998
RKORRM2B-/-	This paper	N/A
Experimental Models: Organisms/Strains		
MICE: Female BALB/c nude were used for xenograft experiments	Charles River, UK	

(Continued on next page)

Continued		
REAGENT or RESOURCE	SOURCE	IDENTIFIER
Oligonucleotides		
siRNA-RRM2B (sequence: UGAGUUUGUAGCUGACAGAUU)	Sigma	Piao et al., 2009
siRNA#2 - RRM2B (sequence: GGAACAAGCUUAAAGCAGA)	Ambion / Life Technologies	s224156
siRNA-p53 (sequence: GUAAUCUACUGGGACGGAA)	Ambion / Life Technologies	Leszczynska et al., 2015
AllStars Negative Control siRNA	QIAGEN	SI03650318
Primers for RRM2B Forward-ChIP (sequence: CTTGCTGGGAAATCTTGACC)	Sigma	Tanaka et al., 2007
Primers used for site-directed mutagenesis Table S1	N/A	N/A
Primers used for dNTP incorporation assay Table S1	N/A	N/A
Primers used for quantitative PCR (qPCR) Table S1	N/A	N/A
Recombinant DNA		
Plasmids used in this work are listed in Table S2	N/A	N/A
Software and Algorithms		
7500 FAST Real-Time PCR thermocycler was used with v2.0.5 software	Applied Biosystems	http://www6.appliedbiosystems.com/support/software/7500/
The software CAVER 3.0 was used for the analysis of the evolution of lateral fenestrations during the MD simulations	N/A	N/A
The particle mesh Ewald (PME) algorithm was used for evaluation of electrostatics interactions	Darden et al., 1993	N/A
The multi time step algorithm Verlet-l/r-RESPA was used to integrate the equations of motion	Tuckerman et al., 1992 ; Verlet, 1967	N/A
The POPS (Parameter OPTimsed Surfaces) algorithm was used for calculation of the Solvent-Accessible Surface Area (SASA) of both proteins RRM2B and RRM2	Cavallo et al., 2003 ; Fraternali and Van Gunsteren, 1996	N/A
The SETTLE algorithm was used for constrained the lengths of covalent bonds involving hydrogen atoms	Miyamoto and Kollman, 1992	N/A
Other		
For the analysis of RRM2B expression and genetic alterations in colorectal cancer datasets the cBioPortal and Prognoscan	http://www.cbioportal.org/ ; http://www.abren.net/Prognoscan/	Gao et al., 2013 ; Cerami et al., 2012 ; Mizuno et al., 2009
Gene Expression Omnibus; Smith et al., 2010	https://www.ncbi.nlm.nih.gov/geo	accession number GSE17536
ICP-MS was performed with ICP-MS Trace Element Analysis	https://www.earth.ox.ac.uk/research/services/geochemical-analysis/icpms/	N/A

CONTACT FOR REAGENT AND RESOURCE SHARING

Further information and requests for reagents may be directed to, and will be fulfilled by, the lead contact, Dr. Ester M. Hammond (ester.hammond@oncology.ox.ac.uk).

EXPERIMENTAL MODEL AND SUBJECT DETAILS

Source of cell lines used in the study is reported in the reagent and resource table.

METHOD DETAILS

Cell culture and treatments

Source of cell lines used in the study is reported in the reagent and resource table. Cells were grown in DMEM with 10% FBS, in a standard humidified incubator at 37°C and 5% CO₂. All cell lines were routinely mycoplasma tested and found to be negative. RKO^{RRM2B^{-/-}} was constructed in this work using CRISPR-Cas9 technology as previously described (Ran et al., 2013). *RRM2B* gene has three isoforms and in order to construct a full knock-out cell line two 20-bp target sgRNA sequences were used targeting exon 1: TTCGGCGGAGTCTGCGCGAT (isoforms 1 and 3) and AAATGTTATTCGCCGCGGTC (isoform 2). Lipofectamine Ltx (Invitrogen) was used for plasmid transfections according to manufacturer's recommendations (the plasmids used are listed in Table S2). Dharma-FECT 1 reagent (Thermo Fisher Scientific) was used for siRNA knockdown according to manufacturer's instructions. RKO or U2OS cells were transfected with the siRNA sequences reported in the reagent and resource table in a final concentration of 50 nM. Drugs were purchased from Sigma unless otherwise stated. Hydroxyurea (HU) was used at a concentration of 2 mM for 6 hr. Adriamycin was used at a concentration of 2 μM for 6 hr. BrdU (5-Bromo-2'-deoxyuridine) was used at a concentration of 20 μM.

Hypoxia treatment

Hypoxia treatments were carried out in a Bactron II anaerobic chamber (Shell labs) or an In vivo₂ 400 (Baker Ruskinn) (for oxygen concentrations at 2%). For experiments at < 0.1% O₂ cells were plated on glass dishes. Cells were harvested inside the chamber with equilibrated solutions. Oxygen concentrations were periodically verified using an Oxylite probe (Oxford Optronix, UK).

Immunoblotting and Immunofluorescence

For immunoblots, cells were lysed in UTB (9 M urea, 75 mM Tris-HCl pH 7.5 and 0.15 M β-mercaptoethanol) and sonicated briefly. The Odyssey infrared imaging technology was used (LI-COR Biosciences) and the Odyssey analysis system was used for quantification of the immunoblots. In each case, experiments were carried out in triplicate and a representative blot is shown unless otherwise stated. The antibodies used in this study are listed in the reagent and resource table.

For immunofluorescence, cells were seeded on autoclaved cover glasses (Menzel-Glaser). At the end of each experiment cells were fixed with 4% fixation buffer (4% (w/v) paraformaldehyde in PBS), lysed with 1% PBS-Triton X-100 and then incubated with blocking buffer (2% (w/v) BSA in 0.1% PBS-Triton X-100). Incubation with the appropriate primary and then secondary antibody followed (diluted in 2% (w/v) BSA - 0.1% PBS-Triton X-100) (antibodies used are listed in the reagent and resource table). Cells were visualized using a LSM780 (Carl Zeiss Microscopy Ltd) confocal microscope. At least 100 cells were counted per condition. Due to the presence of 53BP1 foci in the nuclei of unstressed cells, induction of DNA damage was quantified by counting cells with more than six foci. Induction of ssDNA was quantified by counting cells with more than six RPA32 foci.

RT-qPCR

RNA was prepared using Trizol (Invitrogen/Life Technologies). For qPCR expression analysis cDNA was reverse transcribed from total RNA using Verso kit (Thermo Scientific). qPCR was performed using SYBR Green PCR Master Mix kit (Applied Biosystems) in a 7500 FAST Real-Time PCR thermocycler with v2.0.5 software (Applied Biosystems). mRNA fold change was calculated using a 2^{-ΔΔCt} method in relation to the 18S reference gene. The qPCR graphs show the mean of three biological replicates ± s.e.m. The primers used for qPCR are listed in Table S1.

Flow cytometry (FACS)

FACS analysis was performed as previously described (Olcina et al., 2013). U2OS cells were treated with either RRM2B siRNA or negative control siRNA and were placed in normoxia or < 0.1% O₂ (3 hr). Samples were pulsed with BrdU (20 μM) for 30 min before collection. FACS analysis was carried out using a Becton Dickinson FACSsort. Samples were later analyzed using CellQuest Pro and ModFit LT software. siRNAs and antibodies used are listed in the reagent and resource table.

DNA Fiber analysis and dNTP pool determination

Fiber analysis was carried out as previously described (Foskolou et al., 2016). In brief, sub confluent cells (50%–60% confluency) were sequentially pulse labeled with 25 mM CldU and 250 mM IdU for 20 min each and left at 21% O₂ in a 37°C incubator (normoxic samples). Cells were washed once with fresh warm media before the addition of the second (IdU) label. For hypoxic treated samples, cells were first placed for 2 hr in the hypoxic chamber (< 0.1% O₂) and then treated with 25 mM CldU for the indicated times, followed by the addition of 250 mM IdU for as long as needed for all samples to be in hypoxia for 6 hr in total. At the end of the treatment, labeled cells were lysed and spread with spreading buffer (200 mM Tris-HCl, pH 7.4, 50 mM EDTA, 0.5% SDS) in a tilting the slide. DNA fibers were then fixed with methanol/acetic acid (3:1 ratio) and stained with rat anti-BrdU monoclonal antibody (for detection of CldU labeled tracts) and mouse anti-BrdU monoclonal antibody (for detection of IdU labeled tracts). Source of antibodies is reported in the reagent and resource table. Fibers were imaged using a Bio-Rad Radiance or LSM780 (Carl Zeiss Microscopy Ltd) confocal microscope and analyzed using ImageJ software (NIH). The length of the fiber tracts that had incorporated both labels (CldU and IdU) was measured and replication rates were calculated with the following formula (V_{CldU} (kb/min) = [(x * 0.132 μm) * 2.59 kb / μm] / t (min), where x = length of CldU).

dNTP pool determination in whole-cell extracts was carried out as previously described (D'Angiolella et al., 2012). In brief, cells were seeded in glass dishes and treated either in $< 0.1\%$ O_2 (for the indicated times) or with 2 mM HU (6 hr). The normoxic samples were processed immediately after the beginning of the hypoxic and/or HU treatment. Cells were collected and resuspended in 60% iced cold methanol. Samples were then boiled, centrifuged and the supernatant was dried by centrifugal evaporation and finally dissolved in H_2O . For the preparation of each primer mix a different set of primers was used (listed in Table S1) supplemented with either $[^3H]dATP$ or $[^3H]dTTP$ (PerkinElmer). For dGTP and dCTP determination 1 U of Thermo Sequenase DNA Polymerase (GE Healthcare) was used; for dTTP determination 1.25 U Klenow Fragment (Thermo Fisher Scientific) and for dATP determination 0.625 U Klenow Fragment (Thermo Fisher Scientific) was used. The reactions were started by addition of the enzyme. Reactions were incubated for 1 hr either at 48°C (for dGTP and dCTP mixtures) or at room temperature (for dTTP and dATP mixtures). Following incubation, the reaction mixture were spotted onto Whatman DE81 paper (GE Healthcare) and let dry. The papers were then washed with 5% Na_2HPO_4 , followed by rinsing with distilled H_2O and 100% EtOH. After being dried, the radioactivity on the papers was measured in a LS 6500 Multi-Purpose Scintillation Counter (Beckman Coulter™) using 3.5 mL Optiphase HiSafe 3 (PerkinElmer) counting fluid. Data present percentage of dNTP incorporation compared to the positive control of each experiment. In experiments where both siRNA and hypoxia treatment were used, a normalization to each normoxic control was preceded the final analysis.

Immunoprecipitation (IP) and Chromatin IP (ChIP)

IP was carried out as previously described (Zhou et al., 2003). Briefly, RKO cells were lysed in lysis buffer (100 mM NaCl, 20 mM Tris-HCl pH 7.4, 5 mM $MgCl_2$, 0.5% NP-40) with freshly added phosphatase/protease cocktail inhibitors (Roche). The lysates were incubated with Protein G Sepharose beads (Sigma) and the antibody of interest RRM1 (Santa Cruz Biotechnology: sc-11733) or a control IgG antibody (Invitrogen: A10535) with agitation, at 4°C overnight. Lysates were washed with lysis buffer and solubilized in SDS-PAGE sample buffer. Antibodies used were: RRM1 (Santa Cruz Biotechnology: sc-11733), RRM2B (Santa Cruz Biotechnology: sc-10840), RRM2 (AbD Serotec, MCA3434Z) and for the detection of RRM2 the Pierce Recombinant Protein A/G (Thermo Fisher Scientific, 21186) secondary antibody was used.

ChIP in RKO cells treated as indicated in figure legend was carried out as previously described (Leszczynska et al., 2015). For each sample 2 μg of combined mouse p53 (DO-1; sc-126) and rabbit p53 (FL-393; sc-6243) (Santa Cruz) antibodies were used for immunoprecipitation. Combined non-specific mouse (7076) and rabbit (7074) (Cell Signaling) were used as control IgGs. A no antibody control sample was also included in each experiment. Bound fraction and input were analyzed by qPCR using specific primer set for the *RRM2B* locus: CTTGCTGGGAAATCTTGACC (Tanaka et al., 2007). Fold enrichment is expressed as a % of input and is normalized to total p53 in each sample. Graphs show the mean of technical triplicates $\pm RQ_{max}$ and RQ_{min} ; $n = 3$.

Colony survival and apoptosis

RKO cells were treated either with RRM2B siRNA or negative control siRNA and exposed to normoxia or hypoxia ($< 0.1\%$ O_2 for 24 hr). Subsequently all cells were placed in normoxic incubator and left for 9 days to form colonies, which were visualized by crystal violet staining. Graphs show the mean of three biological replicates \pm s.e.m.

Apoptosis assay were performed as previously described (Leszczynska et al., 2015). In brief, both adherent and floating cells were collected and fixed with 4% paraformaldehyde. Samples were then washed and the nuclei were stained with ProLong Gold mounting medium with DAPI (Thermo Fisher Scientific). Apoptosis was plotted as the percentage of cells with fragmented DNA per field of view, with at least ten fields of view quantified per experiment. Each apoptosis experiment was performed at least 3 times.

xCELLigence proliferation assay

The xCELLigence Real-Time Cell Analyzer (ACEA Biosciences) DP Instrument equipped with an E-Plate was used for proliferation assays. Cells were seeded into 100 μL of media in 96X microplates. The attachment, spreading and proliferation of the cells were monitored every 15 min for 60 hr. For quantification, the cell index at indicated time points was averaged from three independent experiments. Values are presented as mean \pm SEM of three independent experiments.

Xenografts and tissue IF staining

All animal procedures were performed in accordance with current UK legislation and were approved by the University of Oxford Biomedical Services Ethical Review Committee, Oxford, UK. For the tumor growth curves (xenografts), female BALB/c nude mice or female athymic nude mice (Charles River, UK) were randomized and injected subcutaneously with 3×10^6 RKO^{RRM2B+/+} or RKO^{RRM2B-/-} cells in 25% (v/v) matrigel and serum-free DMEM. Tumor growth was monitored until they reached approximately 300-400 mm³ (volume = height x depth x width x $\pi / 6$). For the irradiation experiment, the tumors in half of the animals were irradiated with 10 Gy when tumor volumes reached 100 mm³. Tumors were measured regularly, and tumor growth was plotted as a mean of tumor volumes \pm SEM. Mice were injected with 50 mg/kg of pimonidazole (PIMO) 2 hr before the end of the experiment. Tumors were split in half and either preserved in formalin for wax embedding or were snap frozen and embedded in optimal cutting temperature compound (OCT).

Tissue IF staining were performed as previously described (Leszczynska et al., 2015). In brief, tumors embedded in OCT were sectioned (5 μm) and froze down at $-20^\circ C$. Sections were immediately fixed with 4% paraformaldehyde and then quenched with 50 mM NH_4Cl . Blocking was performed with 1% BSA in TBS, followed by incubation with Mouse on Mouse (M.O.M.) Blocking

Reagent (Vector Laboratories). The sections were stained with PIMO and cleaved caspase-3 primary antibodies, followed by secondary antibodies (listed in the reagent and resource table) and mounted with ProLong Gold mounting medium with DAPI (Invitrogen/Life technologies). The apoptotic cells were counted within and outside of hypoxic regions. Images were taken from at least 3 RKO^{RRM2B+/+} and 3 RKO^{RRM2B-/-} tumors. Graphs show the percentage of apoptotic cells from all normoxic or hypoxic regions.

TCGA RNA-sequencing (RNA-seq) analysis and analysis of colorectal cancer datasets

Raw RNA-seq data for 382 colorectal adenocarcinoma tumors were downloaded from the TCGA project (accessed through cBioportal: <http://www.cbioportal.org/>). To examine tumor-associated HIF-activity (referred to as hypoxia signature), raw data for each sequenced gene were rescaled to set the median equal to 1, and HIF-activity was quantified by averaging the normalized expression of 44 target genes, associated with HIF activity (encoding ADM, GFBP3, EDN2, PFKFB4, FLT1, TFR2, BNIP3L, TGFA, BNIP3, PGK1, EGLN1, LDHA, EGLN3, CP, TGFB3, PFKFB3, HK1, TFRC, EDN1, CDKN1A, CA9, HMOX1, SERPINE1, LOX, NDRG1, CA12, PDK1, VEGFA, ERO1L, RORA, P4HA1, MX1, SLC2A1(GLUT1), STC2, MIF, DDIT4, ENO1, CXCR4, PLOD1, P4HA2, GAPDH, PGAM1, TMEM45A and PIM1) (Li et al., 2014). Log10 conversion of the hypoxia signature was plotted against Log10 conversion of raw data for RRM1, RRM2 and RRM2B. Two-tailed p value shown on each graph for each Pearson and Spearman *r* (correlation coefficient).

To examine tumor-associated p53-activity (referred to as p53 group), raw data for each sequenced gene were rescaled to set the median equal to 1, and p53-activity was quantified by averaging the normalized expression of 6 p53 target genes, associated with hypoxia-induced p53 activity (encoding BTG2, CYFIP2, INPP5D, KANK3, PHLDA3 and SULF2) (Leszczynska et al., 2015, 2016). Log10 conversion of the p53 signature was plotted against Log10 conversion of raw data for RRM2B (also rescaled to set the median equal to 1). Two-tailed p value shown on each graph for each Pearson and Spearman *r* (correlation coefficient).

For the analysis of RRM2B expression and genetic alterations in colorectal cancer datasets the cBioPortal (<http://www.cbioportal.org/>) and Prognoscan (<http://www.abren.net/PrognoScan/>) tools were used on the 5th Dec 2016 (Gao et al., 2013; Cerami et al., 2012; Mizuno et al., 2009). Using cBioPortal the TCGA (provisional) dataset was analyzed (RNA Seq V2 RSEM) for alterations, including mutations, putative copy-number alterations, mRNA expression, mutations and survival probability (629 cancer patients). For the Prognoscan analysis, RRM2B expression was checked in all available colorectal cancer datasets and Kaplan-Meier graphs were extracted only for the statistically significant ($p < 0.05$) dependence between RRM2B expression (probe 223342_at) and survival probability. This analysis used the publicly available dataset at Gene Expression Omnibus (<https://www.ncbi.nlm.nih.gov/geo/>) with the accession number GSE17536 (Smith et al., 2010).

Protein overexpression and purification

The 6 × His-tagged hRRM1 (pET28a-RRM1) was kindly provided by Prof JoAnne Stubbe (Massachusetts Institute of Technology, Cambridge, USA), expressed in *E.coli* BL21-Gold (DE3) competent cells (Agilent Technologies) and as previously described (Ando et al., 2016). The 6 × His-tagged hRRM2 and hRRM2B (pET28a-RRM2, pET28a-RRM2B) were kindly provided by Dr. Yun Yen (Beckman Research Institute at City of Hope, Duarte, USA). The proteins were expressed in *E.coli* BL21-Gold (DE3) competent cells (Agilent Technologies) and purified as previously described (Shao et al., 2004) with minor modifications. Specifically, an overnight culture of the transformed bacteria was diluted 80-fold in 600 mL of 2 × YT medium containing 50 µg/ml kanamycin. Each culture was grown at 37°C until OD_{600nm} = 0.7 - 0.9 and then induced by 1 mM isopropyl-1-thio-β-D-galactopyranoside (IPTG) and incubated overnight at 18°C. Cells were harvested by centrifugation and the pellets were lysed with appropriate amount (5 ml/gr of pellet) Lysis Buffer (50 mM NaH₂PO₄ pH 7.0; 0.1% Triton X-100; 10 mM β-mercaptoethanol; freshly added EDTA-free Protease Inhibitors and DNase I) at 4°C with vigorous agitation until the lysate was homogeneous. The lysate was then sonicated (60% Amplitude 30 s ON / 30 s OFF) and clarified by centrifugation at 48,000 × *g* for 20 min at 4°C. Soluble lysate was passed through a His-Trap HP purification column (GE Healthcare), washed with at least 30-fold bed volume of Wash Buffer (50 mM NaH₂PO₄ pH 7.0; 800 mM NaCl; 50 mM imidazole; 0.1% Triton X-100; 10 mM β-mercaptoethanol) and finally eluted with Elution Buffer (50 mM NaH₂PO₄ pH 7.0; 300 mM NaCl; 125 mM imidazole). The protein then underwent buffer exchange into 25 mM Tris-HCl, pH 7.5 before being concentrated and stored at -80°C. The purified proteins showed approximately 90% purity. The apo-forms of RRM2 and RRM2B recombinant proteins used in ICP-MS experiments were overexpressed and purified as previously described (Wang et al., 2009a). Site-specific mutations in RRM2B (Y164C; Y164F; F183Y; K31E/K151E; Y241H; Y331F and Q127K) were generated by PCR, using the pET28a-RRM2B as a template and the QuickChange II XL Site-Directed Mutagenesis Kit (Agilent Technologies). All constructs were verified by DNA sequencing. Expression and purification of the hRRM2B mutated proteins were performed in the same way as for hRRM2B.

dCDP formation assays

The activity of recombinant RNR was measured using the following reduction method. The enzyme concentration (R1/R2B or R1/R2) was the same in all cases and the limited factor was the presence or not of oxygen (normoxia versus hypoxia). Specifically, a final concentration of 1.25 µM of purified RRM1 was incubated with 2.5 µM of either RRM2 or RRM2B protein. The reaction mixture contained 0.1 mM CDP, 50 mM HEPES (pH 7.5), 6 mM DTT, 8 mM magnesium acetate, 2 mM ATP and 1 mM NADPH in a final volume of 400 µl. The RNR proteins purified were active without reassembling the iron center (Shao et al., 2004; Zhou et al., 2010). In hypoxic

samples (< 0.1% O₂) the reaction mixture was assembled and the assay was carried out within an anaerobic chamber (Bactron, Shel Labs). Reactions were initiated by the addition of CDP, incubated at 37°C and aliquots of 50 μl were quenched by the addition of 10 μl of 3% tricarboxylic acid over a time course of the reaction. Subsequent dCDP and CDP levels were analyzed by HPLC. Graphs present either percentage of dCDP formation when normoxia and hypoxia were compared (data were normalized against the normoxic samples at 37°C at 30 min where the dCDP formation was considered 100%) or in μM when the accumulation of dCDP formed in < 0.1% O₂ at a 0–120 min time course was examined.

Determination of CDP/dCDP

CDP and dCDP levels following RNR activity assays were determined by ion-pairing HPLC with UV detection (270 nm). HPLC was performed using a Shimadzu system with a photodiode array detector. The column was an ACE C 18, 3 μm, 125 × 3 mm (Hichrom) maintained at 35°C. A gradient separation was achieved using 10% methanol, 10 mM KH₂PO₄, 10 mM TBAOH, pH 6.9 (A) and 30% methanol, 50 mM KH₂PO₄, 6 mM TBAOH, pH 7.0 (B), with a linear gradient of 25 – 47% B over 8 min, 47 – 80% B over 1 min, then returning to the started conditions 3 min. The flow rate was 0.6 ml/min and the running time was 16.5 min.

Circular dichroism spectrometry

Circular dichroism (CD) spectra (Chirascan CD/Fluorimeter spectrometer (Applied Photophysics, UK) of hRRM2B and the mutants (0.2 mg/mL) were recorded in the wavelength range 260 to 185 nm in 100 mmol/L potassium phosphate buffer (pH 7.5). All measurements were carried out at 37°C using a 0.1-cm path length quartz cuvette. The data pitch was 0.1 nm with a 1-nm bandwidth at a scan speed of 1.0 nm/s. Each spectrum shown represents the average of three. All CD data were expressed as the mean residue ellipticity, [θ], deg·cm²·dmol⁻¹.

Inductively coupled plasma mass spectrometry (ICP-MS)

The Thermo Finnigan Element 2 ICP-MS was used for quantitation of iron content in the recombinant purified proteins (40 μg of protein was used per 50 μl of reaction). Calibrations were obtained using external standards (a series of standards of known Fe concentrations were prepared and analyzed to gain a calibration linear, prior to the measurement of the samples). An external standard was diluted and measured from a dilution of High Purity Standards 10 ppm ICP-MS-68 A standard. All blanks, standards and samples were also spiked with 1 ng/g Rh, so that any general instrument drift could be normalized. Dilutions were made using a 2% HNO₃ solution, prepared using in-house distilled nitric acid and 18.2 Mohm DI water. All data results were first reported as elemental concentrations and then calculated in nM of Fe per μM of protein. Additional information can be found at (<https://www.earth.ox.ac.uk/research/services/geochemical-analysis/icpms/>).

Electron paramagnetic resonance (EPR)

CW-EPR spectra were collected in the Center for Advanced ESR (CAESR) in the Inorganic Chemistry Laboratory at the University of Oxford. X-band measurements utilized a Bruker-Biospin Micro EMX^{plus} spectrometer equipped with a PremiumX microwave bridge, a cylindrical TE₀₁₁-mode resonator (SHQE-W), an ESR-900 liquid helium cryostat, and an Oxford Instruments ITC-503 s temperature controller. Measurements were performed within the limit of resolution by temperature, 40K, and under non-saturating conditions.

The protein concentration for all EPR samples was 200 μM except for RRM2 protein, which was 70 μM. The protein samples (RRM2B, RRM2 or RRM2B mutants) were diluted in 50 mM HEPES, pH 7.5 and were incubated either at 37°C for 5 min with oxygen present (normoxia) or at 37°C for 60 min in a Bactron II anaerobic chamber (< 0.1% O₂). At the end of each treatment 20% (v/v) glycerol was added for vitrification during the low-temperature recordings. Samples were then transferred to EPR tubes and quick-frozen by immersion in liquid nitrogen. Spin quantitation was performed using the Bruker spectrometer hardware spin calibration, given the input dimensions of the precision Wilmad PQ-706 tubes. The results were verified with a 1 mM Cu^{II} EDTA in 50 mM HEPES pH 7.5, 20% (v/v) glycerol that was measured under non-saturating conditions at 100 K with 50 μW microwave power. The results show spin equivalents per β-subunit.

Molecular Dynamics (MD) simulations

System setup: MD simulations of O₂ transport on hRRM2B (PDB: 3HF1; resolution 2.60 Å) and hRRM2 (PDB: 3VPN; resolution 2.25 Å) were performed (Smith et al., 2009). The RRM2B structure comprises residues S29 to F311. The 3VPN X-ray structure is that of the E106D variant of native RRM2, and comprises residues M65 to M350. Four simulations were performed in which 200 randomly chosen water molecules outside the solvated protein were replaced by 200 O₂ molecules (0.5 M) termed the 100% oxygen level simulation. The random distribution of oxygen molecules precludes any potential artifacts arising from initial distribution. An additional two sets of simulations were performed to control for concentration effects; the first set up has a tenfold reduction in oxygen concentration, termed 10% oxygen level simulation with effective concentration of 50 mM, for RRM2B and RRM2. The second set does not include any oxygen molecules, termed 0% oxygen level simulation. Each system was solvated in a box of dimensions (80, 80, 92) Å using the Solvate plug-in of VMD (Humphrey et al., 1996), with the total system size comprising ~61,000 atoms. In accordance with the Uniprot sequence alignment two mutants of native RRM2B were prepared with the Mutate plugin in VMD (Humphrey et al., 1996), namely Y164C and K37E/K151E.

MD equilibration protocol

Calculations were done with NAMD 2.9 (Phillips et al., 2005), using the CHARMM 27 protein force-field (Brooks et al., 2009) with the CMAP correction (Buck et al., 2006), together with the TIP3P water model (Jorgensen et al., 1983). Oxygen Lennard-Jones parameters were taken from CHARMM (Cohen et al., 2005, 2006). For O₂ gas access in RRM2B and RRM2, the iron centers were modeled using CHARMM 27 force-field, with iron Lennard-Jones parameters $\epsilon_{\text{O}} = 0.00$ kcal/mol and $R_{\text{min}}/2 = 0.65$ Å. Oxygen (O₂) was modeled using CHARMM 27 Lennard-Jones parameters from heme oxygen, $\epsilon_{\text{O}} = -0.12$ kcal/mol and $R_{\text{min}}/2 = 1.7$ Å, as well as bond spring constants and bond spring lengths for O₂ as 1.23 Å and 600 kcal/mol/Å⁻¹, respectively. RRM2B contains the same diiron/dityrosyl cofactor that RRM2 does, and both RRM2B and RRM2 are biologically active as homodimers. In RRM2B, the active site iron coordination environment in Monomer-1 is a mono-iron site, and Monomer-2 has a di-iron site. In RRM2B, the active site iron coordination environment consists in both Monomer-1 and 2 of mono-iron sites.

After 1,000 steps of Conjugate-Gradient minimization, four classical molecular dynamics (MD) simulations of the O₂-containing solvated protein were carried out for 300 ns in the NPT ensemble. The high oxygen concentration was necessary to ensure sufficient sampling of protein cavities by O₂ on the accessible timescale of current simulations. It was verified that no gas clustering occurred in the solvent at this concentrations. The particle mesh Ewald (PME) algorithm was used for evaluation of electrostatics interactions beyond 12 Å, with a PME grid spacing of 1 Å, and NAMD defaults for spline and κ values (Darden et al., 1993). A cut-off at 12 Å was applied to non-bonded forces, both electrostatics and Van der Waals forces were smoothly switched off between the cut-off distance of 12 Å, and the switching distance of 10 Å, using the default NAMD switching function. A Verlet neighbor list with pairlist distance of 14 Å was used to only evaluate non-bonded neighboring forces within the pairlist distance (Verlet, 1967). The lengths of covalent bonds involving hydrogen atoms were constrained by the SETTLE algorithm (Miyamoto and Kollman, 1992) in order to be able to use a 2-fs time-step. The multi time step algorithm Verlet-l/r-RESPA (Tuckerman et al., 1992; Verlet, 1967) was used to integrate the equations of motion. Non-bonded short-range forces were computed for each time step, while long-range electrostatic forces were updated every 2 time steps. The pressure was kept at 1 atm by the Nosé-Hoover Langevin piston (Langevin, 1908; Nosé, 1984a, 1984b), with a damping time constant of 50 fs and a period of 100 fs. The temperature was maintained at 300 K by coupling the system to a Langevin thermostat, with a damping coefficient of 1 ps⁻¹. A total of 3.0 μs of MD simulations were accrued.

Code availability

The standard MPI version 2.9 of the MD simulation code NAMD was employed (Phillips et al., 2005). A free license can be obtained at <http://www.ks.uiuc.edu/Research/namd/>. Version 1.9 of Visual Molecular Dynamics (VMD) was employed for analysis, with license obtained at <http://www.ks.uiuc.edu/Research/vmd/>.

MD simulation analysis

The Solvent-Accessible Surface Area (SASA) of both proteins RRM2B and RRM2 was calculated using the POPS (Parameter OPTimsed Surfaces) algorithm (Cavallo et al., 2003; Fraternali and Van Gunsteren, 1996). The bending angle of helices was estimated using Bendix in VMD (Dahl et al., 2012).

The Diffusion-Reaction Model (Wang et al., 2013) presented in Equation (1) was adopted to describe the diffusion of O₂ into the RNR active site:



This is a kinetic two-step model consisting of an initial diffusion step of the gas molecule, followed by a metal-gas molecule chemical reaction step (Wang et al., 2011; Wang and Blumberger, 2012). Here, a classical force-field (FF) was employed, and only the diffusion and binding of O₂ gas molecules to the RNR iron center were modeled:



The simulation of O₂ diffusing in the solvated RNR enzymes yields diffusion statistics that enable the construction of a probability density map of the O₂-distribution within RNR (RRM2B or RRM2). This distribution is then divided into a set of M discrete protein cluster states that correspond to the probability maxima. Two parameters are used to characterize the diffusion of O₂. First, a distance criterion is established to determine when an oxygen molecule has entered into the active site of hRRM2B and hRRM2, defined as the difference between the center-of-mass (COM) of the iron ion and the O₂ molecule. Second, cut-off criteria of 8 Å, 9 Å and 10 Å were employed to generate statistics of the O₂ entering. An O₂ molecule is counted as having entered the cluster if $d_{\text{COM}}(\text{O}_2\text{-Fe}) < c$ where c is 8 or 9 Å.

Free-energy simulations of tunnel entry

Oxygen entry tunnels were assigned and characterized from classical MD simulations. As previously described, O₂ entry into WT RRM2B and RRM2 was identified to occur primarily through Tunnels T1, T2 and T3. Based on this assignment, equilibrium Adaptive-Biasing Force (ABF) MD simulations (Chipot and Pohorille, 2007; Darve and Pohorille, 2001; Darve et al., 2008; Van Gunsteren, 1989) were performed on oxygen entry into tunnels T1, T2 and T3 in Monomer-1 to determine relative differences in

the thermodynamics of oxygen entry into RRM2B and RRM2. In total, six ABF simulations per RNR were performed, totalling $\approx 0.5 \mu\text{s}$ of MD simulation dynamics. Each ABF simulation was performed with a force bias on a single oxygen molecule meaning these simulations constitute single-molecule biased MD simulations, using the collective variable ξ center-of-mass (COM) distance between Fe(III) and O_2 , $\xi(\mathbf{r}^N) = d(\text{O}_2 - \text{Fe(III)})$, with ξ ranging from 3 \AA to 15 \AA , in bins of width 0.25 \AA . Each ABF simulation obtains ergodic sampling by applying every 500 timesteps a biasing force \mathbf{F}^{ABF} (3) onto the Newtonian equations of motion, whose value is updated on-the-fly (Den Otter, 2000; Den Otter and Briels, 1998) From the result, free-energy gradient along ξ , the Potential of Mean Force (PMF) along ξ is obtained from numerical integration of the gradient.

$$\mathbf{F}^{\text{ABF}} = \nabla_{\mathbf{r}} \tilde{\mathbf{A}} = - \langle \mathbf{E}(\xi) \rangle_{\xi} \nabla_{\mathbf{r}} \xi \quad (3)$$

$$\left(\frac{dG(\xi)}{d\xi} \right) = \left\langle \frac{\partial U(\mathbf{r}^N)}{\partial \xi} \right\rangle - \beta^{-1} \left\langle \frac{\partial \ln |\underline{J}|}{\partial \xi} \right\rangle = - \langle \mathbf{E}(\xi) \rangle_{\xi}. \quad (4)$$

Tunnel T1 in Monomer-1 extends for $\sim 30 \text{ \AA}$ and connects the two faces of the protein. It was simulated as two separate tunnels of length $\sim 15 \text{ \AA}$ in Monomer 1, denoted Tunnel T1 and T1', and was compared to a single simulation of Tunnel T1 in Monomer 2. Two simulations of Tunnels T2 and T3 were performed in RRM2B and RRM2.

Analysis of fenestrations

The software CAVER 3.0 was used for the analysis of the evolution of lateral fenestrations during the MD simulations, using 100 evenly chosen snapshots from the MD simulations, which is every 2 ns. The outer surface of the protein is calculated by rolling a large spherical probe around the surface of the protein and then internal cavities are identified using a smaller spherical probe (a radius of 0.8 \AA was used here, and 12 probe spheres used). All identified tunnels are grouped into clusters based on relative proximities and with an 8 \AA cut off for each cluster node, meaning that tunnels differing from the node by more than 8 \AA are excluded. The values for shell radius and depth (15 \AA) influence the definition of the protein molecular surface.

Statistical analysis

The statistical significance of differences between datasets was determined assessed by using the following test. Student's t test (two-tailed paired, except for dNTP incorporation assays, where a two-tailed unpaired test was applied) was used in all experiments where two means were compared. One-way analysis of variance (ANOVA) was used to compare several means and two-way ANOVA was used for determination in a response that is affected by two factors (one- or two-way ANOVA analysis is indicated at the figure legends). Statistical significance was assumed if $p < 0.05$ or lower and is noted in the figures. Error bars represent mean \pm standard error of the mean (s.e.m.).

DATA AND SOFTWARE AVAILABILITY

Original imaging data have been deposited to Mendeley Data and are available at <http://dx.doi.org/10.17632/bp95v48kgm.1>

Molecular Cell, Volume 66

Supplemental Information


Ribonucleotide Reductase Requires Subunit

Switching in Hypoxia to Maintain DNA Replication


Iosifina P. Foskolou, Christian Jorgensen, Katarzyna B. Leszczynska, Monica M. Olcina, Hanna Tarhonskaya, Bauke Haisma, Vincenzo D'Angiolella, William K. Myers, Carmen Domene, Emily Flashman, and Ester M. Hammond

Figure S1


A




B $<0.1\% O_2$ (h)




C




D




E




F




G




I




J




H




K



M



N



L

RRM2B Alterations	Cases (total)	Cases (relapsed)	Median months disease free
Yes	70	22	39.95
No	473	100	84.23




Figure S2




Figure S3




Figure S4




Figure S5






Figure S6




A

RRM2B EPR Sample	Spins / β subunit ($\times 10^{-3}$)	Hypoxia / Normoxia (%)
Y241H Normoxia	6.85 ± 0.05	72.5 ± 0.5
Y241H $<0.1\% \text{ O}_2$	5 ± 0	
F183Y Normoxia	11.7 ± 1.1	79.5 ± 4.5
F183Y $<0.1\% \text{ O}_2$	9.25 ± 0.35	
Y164F Normoxia	35.5 ± 0.5	60 ± 4
Y164F $<0.1\% \text{ O}_2$	21.25 ± 1.25	
Q127K Normoxia	ND	ND
Q127K $<0.1\% \text{ O}_2$	ND	


B



C



D



E




Figure S1. Related to Figure 1.

(A) Representative images of FACS analysis of RKO and U2OS cells exposed to normoxia or <0.1% O₂ (3 hr) indicating replication stress in hypoxic conditions. Cells were pulsed with BrdU (20 μM) 30 min before collection. (B) Immunoblots for common DDR targets in RKO cells exposed to <0.1% O₂ for the times indicated. (C-F) Immunoblots of RNR subunits in different cancer cell lines exposed to <0.1% O₂ for the times indicated: (C) U87-MG (human glioblastoma); (D) HCT116 (colorectal carcinoma); (E) U2OS (human osteosarcoma) and (F) OE21 (human esophageal). (G) RRM2B levels relatively to β-actin in a panel of different cell lines in normoxia. RKO cells showed the highest expression of RRM2B protein. (H) mRNA levels of RNR subunits in U87-MG cells in <0.1% O₂ normalized to 18S. For all panels n=3 (biological replicates); for panel (H) data show means ± s.e.m. (I) Expression of RRM1 (Log10 conversion) in the colorectal adenocarcinoma TCGA datasets is shown against hypoxia-inducible signature (Log10 conversion). (J) Expression of RRM2 (Log10 conversion) in the colorectal adenocarcinoma TCGA datasets is shown against hypoxia-inducible signature (Log10 conversion). (K) The Cancer Genome Atlas (TCGA) colorectal adenocarcinoma dataset was analyzed for genetic alterations (including mutations, putative copy-number alterations and mRNA expression data (RNA Seq V2 RSEM)) in *RRM2B* gene using cBioPortal. The scheme shows only the 13% cases (83 out of 629), where the genetic alterations in *RRM2B* was found. No mutations were reported. (L) Kaplan-Meier curve showing disease free survival in cancer cases with or without alterations in *RRM2B* from K. (M-N) The expression of RRM2B and the associated survival probability in colorectal cancers using PrognoScan. The colorectal cancer patient dataset GSE17536 was analyzed using PrognoScan tool and overall survival (M), as well as disease-free survival (N) associated with high or low expression of RRM2B (probe 223342_at) are shown in Kaplan-Meier plots.

Figure S2. Related to Figure 2.

(A) Immunoblots of the RNR subunits in RKO^{HIF-1 α +/+} and RKO^{HIF-1 α -/-} cells exposed to <0.1% O₂ for the times indicated. RRM2B protein is induced in hypoxia irrespective of HIF-1 α status. (B) Immunoblots of common replication stress markers in RKO^{HIF-1 α +/+} and RKO^{HIF-1 α -/-} cells exposed to <0.1% O₂ (8 hr). (C) Immunoblots of the RNR subunits in HCT116^{p53+/+} and HCT116^{p53-/-} cells exposed to <0.1% O₂ for the times indicated. RRM2B protein is decreased in the absence of p53. (D) Immunoblots of the replication stress marker RPA32 in HCT116^{p53+/+} and HCT116^{p53-/-} cells exposed to <0.1% O₂ (6 hr). (E-F) Immunoblots (E) and *RRM2B* mRNA levels (F) of H1299 cells treated with either pHRE-p53 or pHRE-LUC and exposed to <0.1% O₂ for the times indicated. (G-H) Immunoblots (G) and *RRM2B* mRNA levels (H) of RKO cells treated with either sip53 or siCTL and exposed to <0.1% O₂ for the times indicated. (I) qPCR for p53 ChIP in HCT116 cells exposed to either normoxia or <0.1% O₂ (6 hr). (J-K) mRNA levels of hypoxia inducible p53 targets *PHLDA3* (J) and *CYFIP2* (K) in RKO cells exposed to <0.1% O₂ normalized to 18S. For all panels n=3 (biological replicates); panels (F, H, J and K) data show mean \pm s.e.m. (I) shows representative mean of technical triplicates \pm RQmax/RQmin. p53 status was examined by two-way ANOVA analysis; (ns) indicates non significant change.

Figure S3. Related to Figure 3.

(A) Immunoprecipitation of RRM1 for the times indicated, followed by immunoblotting for RRM2B in normoxia and <0.1% O₂. (B) Quantification of (A) from n=3 biological replicates. (C) Immunoblots of RNR subunits in RKO cells treated with either siCTL or siRRM2B and exposed to normoxia or <0.1% O₂ (18 hr). Effective depletion of RRM2B protein with the specific siRNA is observed in both conditions. (D) dNTP incorporation assay in RKO cells treated with either siCTL or siRRM2B in normoxia. (E) Representative images of FACS

analysis of U2OS cells treated with either siCTL or siRRM2B and exposed to normoxia or $<0.1\%$ O₂ (3 hr). **(F)** Representative figure of the three isoforms of *RRM2B* gene. Black rectangles represent exons. The colored ovals represent the positions targeted by the guided RNAs in order the RKO^{RRM2B^{-/-}} cell line to be constructed (CRISPR-Cas9 system). **(G)** Immunoblots of RNR subunits in RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} cell lines exposed to normoxia or $<0.1\%$ O₂ (18 hr). **(H)** Immunoblots of p53 status in RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} cell lines exposed to normoxia or $<0.1\%$ O₂ (6 hr). **(I)** Cell proliferation assay in normoxia using the xCELLigence system using RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} cells. For all panels n=3 (biological replicates); for panels (B, D, and I) data show mean \pm s.e.m. and in panel (I) one-way ANOVA analysis was applied; (ns) indicates non significant change.

Figure S4. Related to Figure 3.

(A) Quantification of RPA32 foci in RKO cells treated with either siCTL or siRRM2B after exposure to $<0.1\%$ O₂ for the times indicated. **(B-C)** Quantification of RPA32 foci in RKO (B) or HCT116 (C) cells treated with either siCTL or siRRM2B#2 after exposure to $<0.1\%$ O₂ for the times indicated. **(D-E)** Quantification of 53BP1 foci in RKO cells treated with either siCTL or siRRM2B (D) or siRRM2B#2 (E) after exposure to normoxia or $<0.1\%$ O₂ (6 hr). **(F)** Representative images of 53BP1 foci in RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} cells exposed to normoxia or $<0.1\%$ O₂ (6 hr). Scale bar 20 μ m. **(G)** Immunoblot for PARP cleavage in RKO cells treated with either siCTL or siRRM2B and exposed to normoxia or $<0.1\%$ O₂ (19 hr). **(H)** RKO^{RRM2B^{+/+}} and RKO^{RRM2B^{-/-}} xenografts were grown in mice. Tumor volumes were measured for 5 (RKO^{RRM2B^{+/+}}) and 6 (RKO^{RRM2B^{-/-}}) mice per each group and a mean \pm s.e.m. is shown. For all panels n=3 (biological replicates) otherwise stated; for panels (A-E and H) data show mean \pm s.e.m. and two-tailed Student's t-test was applied; in panel (A) one-way ANOVA analysis was applied; (ns) indicates non significant change.

Figure S5. Related to Figure 4.

(A-B) Recombinant RRM1, RRM2 and RRM2B proteins were overexpressed in *E.coli* cells and purified to ~90% purity as shown with Coomassie blue staining (A) and Immunoblotting (B). (C) Quantitation of iron bound in the RRM2B and RRM2 proteins as overexpressed in *E.coli* cells using ICP-MS. As negative control the apo-forms of the proteins were used. (D) Fold increase of dCDP formation in <0.1% O₂ for the indicated times normalized to 15 min for either R1/R2B or R1/R2 enzymes. Graphs show the amount of dCDP formed after 15 min in <0.1% O₂ and each time point was compared with the previous to determine statistically significant dCDP formation. (E) Substrate consumption (CDP) in normoxia and hypoxia for R1/R2. For panel (C) n=3 (technical replicates); for panels (D-E) n=3 (biological replicates); in all panels data show mean ± s.e.m.; in panel (D) two-tailed Student's t-test was applied; (ns) indicates non significant change. (F) Identification and analysis of the RRM2B and RRM2 oxygen tunnels. MD simulations revealed three principle oxygen cavity tunnels (T1-3) in Monomer-1 in both RRM2B and RRM2 proteins. T1: reveals connectivity between Monomer-1 active site and the outside protein surface, with an average length $29.0 \pm 16 \text{ \AA}$ in RRM2B to $15.0 \pm 15 \text{ \AA}$ in RRM2. T2: reveals connectivity between Monomer-1 and Monomer-2. T3: connects either the Tyr164 (RRM2B) or the Cys202 (RRM2) with the pocket of phenylalanines. (G) Potential of Mean Force for oxygen entry shows differential functioning of RRM2B to RRM2. Comparison between RRM2B (black) and RRM2 (blue) PMF for diffusion (i) T1 and (ii) T1 in Monomer-1, compared to (iii) T1 in Monomer-2; (iv) T2 and (v) T3. The Potential of Mean Force (PMF) for diffusion in the individual tunnels between RRM2B (black) and RRM2 (blue) reveal differences in the tunnels of RRM2B and RRM2. T1 is similar in RRM2B and RRM2, precluding selectivity differences and with oxygen entry characterized by low barriers of 2-3 kcal mol⁻¹, as reported for extended tunnels in [Ni-Fe] hydrogenases (Wang et al., 2011, Wang et al., 2013). T1 in Monomer-2, showed

barriers of 5-6 kcal mol⁻¹, which might explain the lower O₂ turnover of Monomer-2 compared to Monomer-1 in the unbiased MD simulations. T2 appears to show a pronounced difference between RRM2B and RRM2, with a 3 kcal mol⁻¹ higher barrier for O₂ entry into RRM2 compared to RRM2B, as was rationalized in the crystal structure in which the T2 was proposed to be more open in RRM2B compared to RRM2 (Smith et al., 2009). T3 shows barrier height differences between RRM2B and RRM2 and suggest that RRM2B is a superior oxygen-sequestering agent. **(H)** RRM2B has an open phenylalanine channel. The switch of C202 in RRM2 to Y164 in RRM2B results in an open phenylalanine channel specifically in RRM2B.

Figure S6. Related to Figure 5.

(A) Representative figure of the key differences between RRM2 and RRM2B proteins. **(B)** Seven RRM2B variants were constructed with site-directed mutagenesis, overexpressed in *E.coli* cells and purified as shown with Coomassie blue staining to ~90% purity. **(C)** CD spectra of RRM2B WT and variant proteins ensuring that all proteins were properly folded; n=3 (technical replicates). **(D)** Quantitation of iron bound in the RRM2B variant proteins as overexpressed in *E.coli* cells using ICP-MS. **(E-I)** Product formation (dCDP) in <0.1% O₂ for **(E)** Y164F; **(F)** F183Y; **(G)** Y241H; **(H)** Y164C; **(I)** K37E/K151E. n=2 (biological replicates); data show mean ± s.e.m. **(J-K)** The substrate (CDP) over product formation for variants **(J)** Y331F and **(K)** Q127K showed zero turnover as expected. This is because in Y331F variant the pathway that transfers an electron to the catalytic site of RRM1 is disrupted (Xue et al., 2006), while in Q127K variant the stability of the tyrosyl radical cluster is disrupted (Zhou et al., 2010).

Figure S7. Related to Figure 5.

(A) Quantification of EPR spectra of the tyrosyl radical of mutant recombinant RRM2B proteins (Y241H, F183Y, Y164F and Q127K) in normoxia and <0.1% O₂. Data presented show electron spins per β subunit; n=2 (biological replicates); data show means \pm s.e.m. (B-C) Comparison of RRM2B (red) with RRM2 (blue), revealing an open B-helix in RRM2B and a closed B-helix in RRM2. K37E/K151E (green) after 300 ns MD simulation has a closed B-helix. Plots (C) reveal Helix-B bending angle. (D-E) dCTP (D) and dGTP (E) in RKO^{RRM2B-/-} cells transfected with either CTL, WT, Y164C or K37E/K151E and exposed to <0.1% O₂ (16 hr); n=3 (biological replicates); data show means \pm s.e.m. and two-tailed Student's t-test was applied.

Table S1. Primer Table. Related to the STAR Methods.

Oligonucleotide Name	Sequence	Reference
Primers used for quantitative PCR (qPCR)		
<i>18S</i> Forward	TAGAGGGACAAGTGGCGTTC	This paper
<i>18S</i> Reverse	CGGACATCTAAGGGCATCAC	
<i>GLUT-1</i> Forward	ATACTCATGACCATCGCGCTAG	This paper
<i>GLUT-1</i> Reverse	AAAGAAGGCCACAAAGCCAAAG	
<i>RRM1</i> Forward	ACCAACCGCCCACAACCTT	This paper
<i>RRM1</i> Reverse	TGCCATTAGTCCCAGCAATGT	
<i>RRM2</i> Forward	GTGGAGCGATTTAGCCAAGAA	(D'Angiolella et al., 2012)
<i>RRM2</i> Reverse	CACAAGGCATCGTTTCAATGG	
<i>RRM2B</i> Forward	TGGTGGAGCGCTTTAGTCAG	This paper
<i>RRM2B</i> Reverse	CTATCCATCGCAAGGCCCAA	
<i>INPP5D</i> Forward	CGCCCACTAATCCTTGATGT	(Leszczynska et al., 2015)
<i>INPP5D</i> Reverse	GCTTGGACACCATGTTGATG	
<i>CYFIP2</i> Forward	GGTCATGGAGGAACTGCTAA	(Leszczynska et al., 2015)
<i>CYFIP2</i> Reverse	TCTTGGGCATCACCTCTATC	
Primers used for site-directed mutagenesis		
RRM2B_Y164F_For	ATTTAATGCAATTGAAACCATGCCCTT	This paper
RRM2B_Y164F_Rev	TGTTAAGAAAAAAGCAGATTG CAATCTGCTTTTTTCTTAACAAAGGGC ATGGTTTCAATTGCATTAAT	
RRM2B_Y164C_For	ATTTAATGCAATTGAAACCATGCCCTT	This paper
RRM2B_Y164C_Rev	GTGTTAAGAAAAAAGCAGATTG CAATCTGCTTTTTTCTTAACACAGGGC ATGGTTTCAATTGCATTAAT	
RRM2B_K37E_For	GAAGAGCCACTCCTAAGAGAGAGTTC	This paper
RRM2B_K73E_Rev	TCGCCG CGGCGAGAACTCTCTCTTAGGAGTGG CTCTTC	
RRM2B_K151E_For	ACACTTACATCAGAGATCCCAAGGAA	This paper
RRM2B_K151E_Rev	AGGGAATTTTTATTTAATGCA TGCATTAATAAAAAATTCCCTTTCCTT GGGATCTCTGATGTAAGTGT	
RRM2B_F183Y_For	ATGGATAGCAGATAGAAAATCTACTT	This paper
RRM2B_F183Y_Rev	ATGGGGAAAGAGTGG CCACTCTTCCCCATAAGTAGATTTTC TATCTGCTATCCAT	
RRM2B_Y241H_For	ACTTTGCTTGCCTGATGTTCCAACACT	This paper
RRM2B_Y241H_Rev	TAGTAAATAAGCCTTC GAAGGCTTATTTACTAAGTGTGGAA CATCAGGCAAGCAAAGT	

RRM2B_Y331F_For	ATTTCTTTGAGAAACGAGTTTCAGAG TTTCAGCGTTTTGCAG	This paper
RRM2B_Y331F_Rev	CTGCAAAACGCTGAAACTCTGAAACT CGTTTCTCAAAGAAAT	
RRM2B_Q127K_For	GCTCGCTGTTTCTATGGCTTTAAAATT CTCATCGAGAATGTTC	This paper
RRM2B_Q127K_Rev	GAACATTCTCGATGAGAATTTTAAAG CCATAGAAACAGCGAGC	

Primers used for dNTP incorporation assay

dTTP-Forward	TTATTATTATTATTATTATTAGGCGGT GGAGGCGG	(Sherman and Fyfe, 1989)
dCTP-Forward	TTTGTTTGTGGTTTGTGGGCGGTG GAGGCGG	
dGTP-Forward	TTTCTTTCTTTCTTTCTTTTCGGCGGTGG AGGCGG	
dATP-Forward	AAATAAATAAATAAATAAATGGCGGT GGAGGCGG	
dNTP-Reverse	CCGCCTCCACCGCC	

Table S2. Recombinant DNA Table. Related to the STAR Methods.

Plasmid Name	Backbone	Reference
pET28b-6xHis RRM1	pET-28a DNA (Novagen #69865-3)	(Wang et al., 2007)
pET28a-6xHis RRM2	pET-28a DNA (Novagen #69864-3)	(Shao et al., 2004)
pET28a-6xHis RRM2B	pET-28a DNA (Novagen #69864-3)	(Shao et al., 2004)
HA-RRM2B	pcDNA3.1 (Invitrogen; V79520)	(D'Angiolella et al., 2012)
pET28a-6xHis RRM2B ^{Y164F}	pET-28a DNA (Novagen #69864-3)	This paper
pET28a-6xHis RRM2B ^{Y164C}	pET-28a DNA (Novagen #69864-3)	This paper
pET28a-6xHis RRM2B ^{K37E/K151E}	pET-28a DNA (Novagen #69864-3)	This paper
pET28a-6xHis RRM2B ^{F183Y}	pET-28a DNA (Novagen #69864-3)	This paper
pET28a-6xHis RRM2B ^{Y241H}	pET-28a DNA (Novagen #69864-3)	This paper
pET28a-6xHis RRM2B ^{Y331F}	pET-28a DNA (Novagen #69864-3)	This paper
pET28a-6xHis RRM2B ^{Q127K}	pET-28a DNA (Novagen #69864-3)	This paper
pRRM2B ^{WT}	pcDNA3.1 (Invitrogen; V79520)	This paper
pRRM2B ^{Y164C}	pcDNA3.1 (Invitrogen; V79520)	This paper
pRRM2B ^{K37E/K151E}	pcDNA3.1 (Invitrogen; V79520)	This paper
pRRM2B ^{Q127K}	pcDNA3.1 (Invitrogen; V79520)	This paper
pHRE-p53	pGL3-basic 5xHRE (Promega; E1751)	(Hammond et al., 2006)
pHRE-LUC	pGL3-basic 5xHRE (Promega; E1751)	(Hammond et al., 2006)
SpCas9-GFP-RRM2B_1/3	pSpCas9(BB)-2A-GFP (Addgene; 48138)	This paper
SpCas9-GFP-RRM2B_2	pSpCas9(BB)-2A-GFP (Addgene; 48138)	This paper